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Membrane transport mechanisms involved in homeostasis of the NMDA receptor
coagonists L-glutamate and D-serine
Chairperson: Michael P. Kavanaugh, Ph.D.
Glutamate is the predominant excitatory neurotransmitter in the mammalian central
nervous system. Glutamate release and reuptake control both tonic activation of glutamate
receptors and phasic signaling during synaptic transmission. Here we study different
aspects of the system. The first three chapters focus on the most abundant glutamate
transporters found in the brain, excitatory amino acid transporters 1-3 (EAAT13/SLC1A3,2,1). The last chapter is devoted to a paralogous neutral amino acid transporter
(ASCT1/SLC1A4) and its role in transport of D-serine, a coagonist of the N-methyl-Daspartate (NMDA) glutamate receptor.
In the first chapter, we discuss the existing discrepancy in estimates of EAAT1-3
turnover rates in the research literature. We talk about the general approach used for the
data analysis and its pitfalls. We use a boundary function method to construct a reduced
model that describes the kinetics of EAAT1-3, and we use it to derive an independent and
statistically reliable estimate of turnover rates (15, 24, and 2 glutamate molecules per
second for EAAT1-3, respectively). We discuss and compare our results to the ones
existing in the literature. We create a 3-D diffusion model of synaptic transmission using
these turnover rates, as a proof of concept. We show that the simulation is consistent with
previously reported time-course of glutamate in the synaptic cleft.
The second chapter is devoted to studying the efficacy of the transporters and their
ability to create a significant diffusion gradient near the membrane surface. We continue
the discussion from the previous chapter about the importance of an ambient glutamate
level. There is a 100-fold discrepancy in the glutamate concentration estimates between
two different methodologies in the literature. Electrophysiological studies are consistent
with 25-87 nM glutamate concentration, while microdialysis studies suggest >2 μM
glutamate concentration. We address this issue by constructing another mathematical
model that provides a potential explanation for such discrepant results.
In the third chapter, we focus on a novel photosensitive EAAT blocker, an
azobenzene derivative of TFB-TBOA named azo-TFB-TBOA (ATT). The drug rapidly
shifts between its cis- and trans- conformations upon the stimulation with 350nm or 450nm
wavelength light, respectively. The drug's affinity for each EAAT subtype is also changed
with its conformational structure.
In the fourth chapter, we focus on D-serine homeostasis, an endogenous NMDA
receptor coagonist. We investigate ASCT1 transporter (also known as SLC1A4) and
propose it to be the prime source of extracellular D-serine in the brain. We also study a
new ASCT1/SLC1A4 blocker, 3-biphenyl-4-hydroxyproline (BiPro), as potentially
valuable research and therapeutic tool.
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INTRODUCTION
A. Glutamate as a neurotransmitter
Glutamate is the predominant excitatory neurotransmitter in the mammalian
central nervous system (CNS). About 80% of all synapses in mammalian CNS are
glutamatergic (Harris, 1994). It plays crucial roles not only in excitatory synaptic
transmission but also in synaptic plasticity, neurodevelopment, and neurodegeneration.
Dysregulation of glutamatergic signaling is associated with various neurological diseases
and psychiatric disorders such as schizophrenia, attention-deficit/hyperactivity disorder
(ADHD), epilepsy, Alzheimer’s disease, cerebral ischemia, traumatic brain injury, and
others (for review see Miladinovic 2015). Its wide-spread presence in the brain and its
involvement in many biochemical pathways played a significant role in delaying the
acceptance of glutamate as a neurotransmitter. Glutamate’s concentration in the brain is
higher than any other amino acid, about 5–15 mmol per kg of tissue, depending on the
region (Schousboe 1981). Its central role in brain metabolism was noted more than 80
years ago (Krebs 1935). Although its excitatory properties have been reported since the
1950s (Hayashi 1952; Curtis and Watkins 1960), it took about 20 more years before
glutamate

was

widely

recognized

as

a

fundamentally

important

excitatory

neurotransmitter (for reviews see Fonnum 1984; Meldrum 2000; Watkins 2000; Danbolt
2001; Zhou and Danbolt 2014).
Over the last few decades, families of glutamate receptors and transporters were
identified. Advancement in molecular genetics, electrophysiological and biochemical
approaches allow for greater insight into the nature of glutamate signaling that is
controlled by interactions among these molecules. Finally, computational progress gives
1

an unprecedented opportunity for modeling and simulation of processes on a cellular and
molecular level. In this section of introduction, we focus on the necessary background
concerning the structure of the glutamatergic synapse, the function of glutamate receptors
and transporters, and on an overview of mathematical modeling approaches to better
understand these functions.

1. Glutamate release
Glutamate is mainly found intracellularly, with the highest concentrations found
inside axon terminals (5-10 mM; Bramham et al., 1990; Ottersen et al., 1990; Ottersen et
al., 1992; Storm-Mathisen et al., 1992; Osen et al., 1995; Ottersen et al.,1996; Danbolt
2001). Even the highest estimates of extracellular concentration are much lower (e.g.,
Benveniste et al. 1984; Takagi et al. 1993; Wahl et al. 1994; Baker et al. 2002). In the
nerve terminals, cytoplasmic glutamate is transported into synaptic vesicles (SVs) by
members of SLC17 solute carrier family: VGLUT1-3 (SLC17A7, SLC17A6, and SLC17A8,
respectively; for review see Omote et al. 2011). The concentration of glutamate inside
SVs reaches levels higher than 100 mM, with about 3000 molecules per vesicle (Riveros
et al. 1986; Burger et al. 1989; Shupliakov et al. 1992; Martineau et al. 2017). When an
action potential reaches the axon terminal, it forces voltage-gated calcium channels in the
active zone to open, increasing cytoplasmic Ca 2+ concentration. SVs release their
glutamate content into the synaptic cleft in a Ca2+-dependent manner through exocytosis
(Fernandez-Chacon and Sudhof 1999; Takamori et al. 2006). The neurotransmitter
diffuses across the synaptic cleft and reaches the surface of the postsynaptic neuron. The
postsynaptic neuron membrane contains a protein complex called postsynaptic density
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(PSD), which includes ionotropic glutamate receptors, scaffold proteins, and many others
(for review see Ziff 1997; Kennedy 2000). Glutamate then activates the receptors, causing
an excitatory postsynaptic potential (EPSP) in the postsynaptic cell and, if integration of
synaptic potentials exceeds the threshold, an action potential.

Many synapses are

partially enveloped by astrocytes, that help control synapse environment and functions
(Ventura and Harris, 1999; Chung et al., 2015; Haydon and Nedergaard, 2015; Allen and
Eroglu, 2018).

2. Glutamate receptors
There are two distinct types of glutamate receptors: ionotropic (iGluR) and
metabotropic (mGluR). Ionotropic receptors contain an intrinsic cation channel gated by
glutamate and they can be subdivided based on their pharmacology. N-methyl-Daspartate (NMDA) was one of the initially synthesized variants of glutamic and aspartic
acid that displayed excitatory properties when applied to neurons (Watkins 1962; Curtis
and Watkins 1963). Reports followed of naturally occurring excitatory kainic and
quisqualic acids (Shinozaki and Konishi 1970; Shinozaki and Shibuya 1974; Biscoe et al.,
1975), and a synthesized analog of ibotenic acid, called α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA) (Krogsgaard-Larsen et al. 1980). Later, the first mGluR
specific agonist, L-2-amino-4-phosphonobutyric acid (L-AP4), was found, although it was
considered an antagonist at first. (Koerner and Cotman 1981; Davis and Watkins 1982;
Evans et al. 1982; Butcher et al. 1983; Monaghan et al. 1983; Robinson et al. 1985;
Slaughter and Miller 1985; Butcher et al. 1986). These compounds and others helped to
identify the first mGluRs (Group III mGluRs; previously named L-AP4 receptors), and
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three known subtypes of iGluRs: NMDA receptors, AMPA receptors (previously named
quisqualate receptors), and kainate (KA) receptors (for review see Watkins and Evans
1981; McLennan 1983; Foster and Evans 1984; Sharif 1985; Mayer and Westbrook 1987;
Watkins and Olverman 1987; Collingridge and Lester 1989; Monaghan et al. 1989;
Hansen and Krogsgaard-Larsen 1990). Later molecular cloning showed the existence of
three corresponding ionotropic glutamate receptor subfamilies. We will not discuss the
metabotropic glutamate receptor here (for a review, see e.g., Niswender and Conn,
2010).
The ionotropic glutamate receptors families can thus be conveniently identified
based on the pharmacological agonist discussed previously: AMPA, kainate, and NMDA
(for a review see e.g., Lodge 2009; Traynelis et al., 2010; Kumar and Mayer, 2013). There
is also a fourth class of ionotropic glutamate receptors, so-called delta receptors, but they
do not function as ion channels under normal conditions and will not be discussed here
(Yuzaki and Aricescu, 2017). All ionotropic receptors are tetramers comprised of several
subunit subfamilies, as described below.

i. AMPA receptors
AMPA receptors are characterized by fast kinetics and generally low permeability
to divalent cations. They are primarily responsible for the fast portion of an excitatory
response to glutamate (Monaghan et al. 1989; Digledine et al. 1999). AMPA receptors
also activate in response to kainate, although, with lower affinity; moreover kainateinduced current does not desensitize, unlike glutamate- and AMPA-induced responses
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(Hollmann et al. 1989; Boulter et al., 1990; Sommer et al. 1990; Kawamoto et al. 1991;
Gallo et al., 1992; Hollmann et al. 1989; Sun et al., 1992).
The group consists of four subunits GluA1-4 (also known as GluR1-4). The
subunits have 68-73% sequence homology with each other (Hollmann et al. 1989; Boulter
et al., 1990; Keinaner et al., 1990; Nakanishi et al., 1990; Sakimura et al., 1990; Puckett
et al., 1991; Gallo et al., 1992; Potier et al., 1992; Sun et al., 1992). The subunits
assemble into a tetramer (dimer of dimers) in different combinations to form an AMPA
receptor (Rosenmund et al. 1998; Chenet al. 1999; Ayalon and Stern-Bach 2001;
Safferling et al. 2001; Tichelaar et al. 2004). The combination of subunits determines the
stochiometric properties of the receptor. For example, the lack of the GluA2 subunit in
recombinant receptors allows the permeation of not only monovalent cations but Ca2+
ions as well (Hollman et al. 1991; Verdoorn et al. 1991; Burnashev et al. 1992; Muller et
al. 1992). This particular property is also modified through RNA editing that leads to a
change in a single amino acid in a transmembrane domain. Interestingly, the editing
process occurs specifically in GluA2, although all other GluA subunits have a similar
domain sequence. It is believed to be due to a certain crucial intron sequence specific to
GluA2 (Sommer et al., 1991; Egebjerg et al., 1994). Note that most AMPA receptors in
the brain have the GluA2 subunit and do not conduct calcium ions (Iino et al. 1990;
Nakanishi 1992; Wenthold et al. 1996; Rosenmund et al. 1998; Greger et al. 2002).
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ii. Kainate receptors
Similarly to the AMPA receptors, kainate receptors can activate in response to
AMPA and kainate (KA), with a higher affinity for KA (Sommer and Seeburg 1992). The
absence of specific compounds slowed down the research of these receptors. Kainate
receptors are widely distributed throughout the brain both post- and presynaptically (see
e.g., Lerma et al. 2001; Huettner 2003). While AMPA and NMDA receptors play a
predominant role in excitation of the postsynaptic cells, KA receptors modulate
neurotransmitter release presynaptically and neuronal excitability postsynaptically (for
reviews see e.g., Huettner 2003; Lerma 2003; Contractor et al., 2011; Sihra and
Rodríguez-Moreno 2013). Moreover, there is accumulating evidence that KA receptors
can also signal through G-proteins (Rodrigues and Lerma 2012).
The KA receptor group includes subunits from two groups. The first group contains
three subunits GluK1-3 (also known as GluR5-7), which are 75-80% homologous with
each other, and about 40% homologous with AMPA receptors subunits GluA1-4 (Bettler
et al. 1990; Egebjerg et al. 1991; Bettler et al. 1992; Morita et al. 1992; Sommer and
Seeburg 1992). The homomeric receptors formed by these subunits in oocytes and
cultured cells are functional and reported to have different properties. Interestingly, AMPA
activates only GluK1 receptors. In all cases, the current completely desensitizes (unlike
the already mentioned KA-induced current in AMPA receptors). Nevertheless, [ 3H]kainate
experiments showed a similar affinity of KA to GluK1-3. (Bettler et al., 1990; Egebjerg et
al. 1991; Sommer et al., 1992; Sommer and Seeburg 1992; Lomeli et al., 1992; Schiffer
et al. 1997). The second group contains two subunits GluK4-5 (also known as KA1-2),
that are 70% homologous with each other, 43% homologous with the subunits of the first

6

group GluK1-3, and 37% homologous with AMPA receptors subunits GluA1-4. Unlike
GluK1-3, the GluK4-5 homomeric receptors do not appear to be functional when
expressed in oocytes and cultured cells as no detectable currents were recorded. The
experiments with [3H]kainate and [3H]AMPA showed even higher affinity of GluK4-5 for
KA than that of GluK1-3, and no noticeable binding of AMPA. Finally, the co-expression
of different subunits GluK1-2 or one of the GluK1-3 subunits with GluK4-5 in different
combinations resulted in functional heteromeric receptors with distinct properties unseen
in homomeric GluK1-3 receptors. For example, GluK1/GluK5 receptors exhibit nondesensitizing AMPA-induced current (Werner et al., 1991; Herb et al., 1992; Kamboj et
al., 1992; Lomeli et al., 1992; Sakimura et al., 1992; Heckmann et al. 1996; Swanson et
al., 1996; Schiffer et al. 1997; Cui and Mayer 1999; Dingledine et al., 1999).

iii. NMDA receptors
Most glutamate excitatory synapses coexpress AMPA and NMDA receptors (Dale
and Roberts, 1985; Huettner and Baughman, 1988; Forsythe and Westbrook, 1988;
Bekkers and Stevens, 1989; McBain and Dingledine, 1992; Silver et al., 1992). NMDA
receptors have several distinct features that separate them from AMPA receptors. Firstly,
they activate and desensitize slower compared to AMPA receptors (Hestrin et al., 1990;
Sah et al., 1990; Trussell et al., 1993; Geiger et al., 1997; Gotz et al., 1997). Secondly,
the NMDA receptor pore is blocked by Mg2+ ions; the blockage is relieved with membrane
depolarization (Mayer et al., 1984; Nowak et al., 1984; Hsiao et al., 2002). Thirdly, NMDA
receptor activation requires binding of not only glutamate but a second coagonist: glycine
or D-serine (Johnson and Ascher, 1987; Verdoorn et al., 1987; Kleckner and Dingledine,
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1988; Vyklicky et al., 1990; Benveniste and Mayer, 1991; Clements and Westbrook,
1991; Schell et al., 1995; Mothet et al., 2000). NMDA receptors present not only in
synapses but also outside of them, and the type of coagonist is thought to depend on this
localization (Papouin et al., 2012). Nevertheless, both coagonists appear to be present in
the extracellular solution at non-saturating levels in their respective brain regions
(Hashimoto et al., 1993; Schell et al., 1995; Hashimoto and Oka, 1997; Schell et al., 1997;
Bergeron et al., 1998; Billups and Attwell, 2003). Fourthly, NMDA receptors are highly
permeably to Ca2+ ions, which initiates a cascade of intracellular events in the
postsynaptic neuron that eventually affect synaptic plasticity (for review see e.g.,
Traynelis et al., 2010; Paoletti et al., 2013; Volianskis et al., 2015).
Magnesium ions prevent the activation of NMDA receptors unless the postsynaptic
neuron is already depolarized. Thus, NMDA receptors do not play a role in the initiation
of synaptic transmission and require a co-expression of other receptors to be functional.
Synapses expressing only NMDA receptors are called silent synapses, and they never
conduct a signal (Isaac et al. 1995; Liao et al. 1995). When postsynaptic neuron is
depolarized, i.e., during persistent signaling of the presynaptic neuron and activation of a
postsynaptic neuron through AMPA receptors, NMDA receptors open and allow the influx
of calcium ions. As previously stated, the calcium ion influx triggers a cascade of events
that lead to a change in synaptic strength (for review see e.g., Traynelis et al., 2010;
Paoletti et al., 2013; Volianskis et al., 2015). Interestingly, the pattern of NMDAdependent Ca2+ influx dictates whether the synaptic strength will be increased (long term
potentiation; LTP) or decreased (long term depression; LTD) (Malenka et al., 1994). This
synaptic plasticity provides a straightforward explanation of the nature of memory and the
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learning process (for a review, see e.g., Cooke 2006, Nicoll 2017). On the other hand,
overstimulation of NMDA receptors and an excess influx of Ca 2+ into the cell lead to
overactivation of several enzymes and signaling pathways (Dirnagl et al., 1999). This
process is called excitotoxicity and usually results in neural death (Bano and Nicotera,
2007; Szydlowska and Tymianski, 2010). To no surprise, the dysregulation of NMDA
receptors is associated with various diseases and disorder, such as schizophrenia
(Mueller and Meador-Woodruff, 2004; Henson et al., 2010), neurodegenerative disease
(Fan and Raymond, 2007; Zhang et al., 2016; Vanle et al., 2018; Liu et al., 2019), stroke
(Lai et al., 2011; Wu and Tymianski 2018), and others.
NMDA receptor group consists of seven subunits across three subfamilies: GluN1,
GluN2A-D, and GluN3A-B. These subfamilies have low homology (about 25%) between
each other and other iGluR families, and about 50-60% sequence similarity within a
subfamily (Moriyoshi et al., 1991; Ikeda et al., 1992, Kutsuwada et al., 1992, Meguro et
al., 1992, Monyer et al., 1992; Sucher et al., 1995; Matsuda et al.,2002). NMDA receptors
are heteromers and consist of four subunits like the rest of the iGluRs. The most studied,
and most abundant, NMDA receptors consist of two GluN1 subunits, which bind glycine
or D-serine, and two GluN2 subunits, which bind glutamate (Laube et al., 1997; Kuryatov
et al.,1994; Hirai et al., 1996; Furukawa et al., 2005; Tovar et al., 2013; Karakas and
Furukawa, 2014). The subtype and composition of GluN2 subunits regulate the
stoichiometric properties of the receptor, such as Mg2+ sensitivity and channel
conductance (Monyer et al., 1992; Stern et al., 1992; Wollmuth et al., 1998). GluN3
subunits are reported to bind glycine, and they seem to play regulatory roles, e.g., they
affect dendritic spine density (Das et al., 1998; Roberts et al., 2009), but also affects Ca 2+
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permeability (Chatterton et al., 2002; Sasaki et al., 2002; Matsuda et al., 2003; Cavara
and Hollman, 2008; Henson et al., 2010). GluN3 is also reported to play an important role
during early postnatal development when its expression is the highest, before dropping
sharply in adulthood (for review see Pérez-Otaño et al., 2016). Elucidating the
physiological roles of GluN3, including expression patterns and function, requires further
research.

3. Glutamate uptake
Glutamate ambient concentration in the synaptic cleft rises sharply during
transmission but decays within milliseconds (Clements et al., 1992). The rapid clearance
of the synaptic cleft from the glutamate is necessary for effective signaling. Moreover,
prolonged activation of glutamate receptors leads to excitotoxicity, as already discussed.
Glutamate is not metabolized in the extracellular space. Instead, its concentration is
controlled by transmembrane transporter proteins: excitatory amino acid transporters
(EAATs). This section provides a short overview of the structure and notable features of
EAATs (for in-depth review see e.g., Danbolt, 2001; Tzingounis and Wadiche, 2007;
Danbolt et al., 2016).
EAATs are members of the solute carrier family (SLC1) that include five members:
EAAT1 (also known as SLC1A3 or GLAST), EAAT2 (SLC1A2 or GLT-1), EAAT3
(SLC1A1 or EAAC1), EAAT4 (SLC1A6), and EAAT5 (SLC1A7). The first identified
transporter of this family was EAAT2 (Danbolt et al., 1990; Pines et al., 1992) that
localizes to glial cells (Danbolt et al. 1992; Levy et al. 1993) and axon terminals (Holmseth
et al., 2012; Danbolt et al., 2016). EAAT1 and EAAT3 were discovered shortly after
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(Storck et al., 1992; Tanaka et al., 1993; Kanai and Hediger 1992; Kanai et al., 1993;
Bjørås et al. 1996). EAAT1 resides in astroglia (Lehre et al., 1993; Lehre et al., 1995;
Schmitt et al., 1997). EAAT3 localizes in neuronal bodies and dendrites (Shashidharan
et al., 1997; Cheng et al., 2002; Holmseth et al.,2012). EAAT4 (Fairman et al., 1995) is
found predominantly on Purkinje cells of the cerebellum (Dehnes et al., 1998; Lin et al.,
1998; Massie et al., 2008). EAAT5 (Arriza et al., 1997) is localized predominantly to retinal
neurons (Eliasof et al., 1998; Veruki et al., 2006).
All members of the EAAT family are exchangers that co-transport 1 glutamate
molecule, 3 Na+, 1 H+, and counter-transport 1 K+ (Zerangue and Kavanaugh, 1996; Levy
et al., 1998). Moreover, EAATs conduct chloride ions, which is thermodynamically
uncoupled from glutamate uptake (Fairman et al. 1995; Wadiche et al., 1995; Ryan and
Mindell 2007). EAAT4-5 have the highest chloride conductance among all EAATs and, at
the same time, the slowest transport cycle. About 95-100% of the glutamate-induced
current in EAAT4-5 was anion current, which makes them act more like chloride channels
rather than glutamate transporters (Palmer et al., 2003; Mim et al., 2005; Gameiro et al.,
2011).
EAATs are homotrimers that form a bowl-shaped aqueous cavity, that extends
halfway across the membrane, with three independent binding sites (Yernool et al. 2004;
Grewer et al., 2005; Leary et al., 2007; Ruan et al., 2017). This structure appears to
facilitate transporter function by lowering the energy barrier for ions to cross the cell
membrane (Yernool et al. 2004; Gouaux and Mackinnon, 2005), and by creating a
diffusion barrier decreasing the effective rate of glutamate unbinding from the trimer
(Leary et al., 2011).
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B. D-serine is an endogenous NMDA receptor coagonist
NMDARs are activated by binding two molecules of neurotransmitter glutamate to
its GluN2 subunits and two molecules of a coagonist: glycine or D-serine, to its
GluN1/GluN3 subunits (Laube et al., 1997; Kuryatov et al.,1994; Hirai et al., 1996;
Furukawa et al., 2005; Yao et al., 2008; Tovar et al., 2013; Karakas and Furukawa, 2014;
Mothet et al., 2015). It was proposed that D-serine acts on synaptic NMDA receptors,
while glycine is the main coagonist for extrasynaptic NMDA receptors (Papouin et al.,
2012). Numerous studies suggest the importance of D-Serine in synaptic NMDAR
activation in the cortex, (e.g., Mothet et al., 2000; Hennenberger et al., 2010;
Radzishevsky et al., 2013; Le Bail et al., 2015, Mothet et al., 2015). Some recent studies
also report its importance in the wake-sleep cycle (Papouin et al., 2017). The
dysregulation of D-serine is associated with such disorders as schizophrenia, epilepsy,
and Alzheimer’s disease (Yamamori et al., 2014; Bardaweel et al., 2014; Balu and Coyle,
2015; Kantrowitz et al., 2015; Madeira et al., 2015), as well as age-related cognitive
decline (Potier et al., 2010; Panizzutti et al., 2014). However, the mechanisms that
establish the ambient levels of D-Serine are not completely known.
D-serine is synthesized from L-serine via serine racemase (Wolosker et al., 1999),
an intracellular enzyme serine racemase primarily located in neurons (Balu et al., 2014;
Wolosker et al., 2016). D-serine is likely to be released from the neurons by the
heterodimeric sodium-independent L- and D- amino acid exchanger SLC7A10 (also
known as ASC1) (Fukasawa et al., 2000; Helboe et al., 2003; Foster et al., 2016;
Wolosker et al. 2016; Sason et al., 2017). D-serine degradation is catalyzed by an enzyme
D-amino acid oxidase (Nagata, 1992), which is primarily expressed in glial cells (Sacchi
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et al., 2012). It is logical to assume that there exists at least one type of transporters that
facilitate the uptake of ambient D-serine into glial cells, but none were identified until very
recently. Foster et al., (2016) showed that both SLC1A4 (also known as ASCT1) and
SLC1A5 (ASCT2) transport D-serine despite a previously report that D-serine was not a
substrate of SLC1A4 (Shafqat et al., 1993). While SLC1A5 is mainly expressed outside
of CNS (Utsunomiya-Tate et al., 1996), SLC1A4 is strongly expressed in the brain (Arriza
et al., 1993), making it a good candidate for the missing link. Figure 1 shows the
hypothesized system of influx-efflux of D-serine.
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C. Modeling in neuroscience
One of the earliest mathematical models in neuroscience is also one of the most
famous, the Hodgkin and Huxley model of the action potential in the squid giant axon
(Hodgkin and Huxley, 1952). In this model the cell was represented by an electrical circuit
with cell components being electrical elements (capacitor for a cell membrane,
conductors with varying properties for ion channels). The model has been successful in
both describing and predicting a great number of neuronal properties. It was followed by
the modeling of ion channels based on discrete chemical states of the channel and
stochastic transitions between them (e.g., Castillo and Katz, 1957; Karlin 1967; Katz and
Milede, 1972; Anderson and Stevens, 1973; Colquhoun 1973). Unfortunately, there are
only a handful of differential equations that could be solved analytically. With a limiting
computational power at that time, the modeling was restricted to special cases that can
be solved without the use of numerical methods, such as Michaelis-Menten model,
Monod-Wyman-Changeux model, simple linear cases, etc. (e.g., Monod et al., 1965,
Colquhoun and Hawkes, 1977). The field continued to evolve with modeling of diffusion
of a neurotransmitter in a synapse (Clements, 1996; Barbour and Häusser, 1997) and
outside of it (Rusakov and Kullmann, 1998; Rusakov et al., 1999). About at the same
time, the more complex Markov models of receptors and transporters started to appear
(e.g., Benveniste et al., 1990; Wadiche and Kavanaugh, 1998).
New knowledge led to the construction of more detailed and complicated models.
They better reflected the nature of processes but, naturally, included more parameters or
variables. There are numerous examples of such development for the Hodgkin and
Huxley model (e.g., Traub et al., 1994; Bower and Beeman, 1998; Cornelis et al. 2012),
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synaptic diffusion model (Savtchenko and Rusakov, 2007; Scimemi et al., 2009;
Savtchenko et al., 2013), and Markov models (Nahum-Levy et al., 2001; Wadiche and
Jahr, 2001; Schorge et al., 2005; Iacobucci and Popescu, 2018). However, the increasing
numbers of parameters and variables in pursue of more realistic models gave rise to
another problem, called overparameterization. Overparameterization occurs when one or
more parameters cannot be discerned from the available data. For example, it is often
impossible to definitively distinguish between two Markov models with many hidden
states, i.e., non-directly observable states, in a statistically reliable manner. The
overparameterized model is not sensitive to some of its parameters, and, as a result, their
estimates may vary greatly without any change in the model output. Often, the
combinations of parameters or variables determine the behavior of the model, rather than
individual ones (e.g., Ori et al., 2018). In that case, the model should be redefined in terms
of these combinations. Nevertheless, the overparameterization problem is often
overlooked, and statistically unreliable estimates of parameters are reported. While these
values do not matter much in terms of the model they were reported in, issues arise when
the same reported values are used in different settings and models, where errors may
have a significant effect. In the following sections we describe one of the possible
solutions to the problem: model reduction. We utilize a mathematical technique, called
boundary function method (Vasil’eva et al., 1995), that allows one to reduce number of
variables and parameters of a model under certain conditions. The resulting reduced
model is easier to solve and analyze, while its solution can be made to be arbitrary close
to the solution of the original problem.
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ABSTRACT
Excitatory Amino Acid Transporters (EAATs) operate over wide time scales in the
brain. They maintain low ambient concentrations of the primary excitatory amino acid
neurotransmitter glutamate, but they also seem to play a significant role in clearing
glutamate from the synaptic cleft in the millisecond time-scale process of chemical
communication that occurs between neurons. The detailed kinetic mechanisms
underlying glutamate uptake and clearance remain incompletely understood. In this work
we used a combination of methods to model EAAT kinetics and gain insight into the
impact of transport on glutamate dynamics in a general sense. We derive reliable
estimates of the turnover rates of the three major EAAT subtypes expressed in the
mammalian cerebral cortex. Previous studies have provided transporter kinetic estimates
that vary over an order of magnitude. The values obtained in this study are consistent
with estimates that suggest the unitary transporter rates are approximately 20-fold slower
than the time course of glutamate in the synapse. A combined diffusion/transport model
provides a possible mechanism for the apparent discrepancy.
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1. INTRODUCTION
Neurons and surrounding glial cells are the primary functional and structural units
of central and peripheral nervous systems. A neuron is an electrically excitable cell that
receives, integrates, and transmits information by a combination of electrical and
chemical neurotransmitter signaling. Rapid synaptic transmission involves release of
neurotransmitter from presynaptic neuron terminals followed by diffusion across a
synaptic gap and binding to postsynaptic receptors that transduce the chemical signal
into an electrical signal in the postsynaptic cell (see Figure 1). Functions of glial cells
include support and homeostatic maintenance of the neuron’s environment, and in some
cases, reuptake of neurotransmitter. In mammalian brain, excitatory synaptic
transmission is mediated predominantly by the neurotransmitter glutamate. In this work
we focus on the transport and diffusion mechanisms involved in controlling glutamate
concentration changes during the signaling process. Data from a number of studies is
consistent with the idea that glutamate transporters maintain low ambient concentrations
to prevent persistent glutamate receptor activation [7, 15, 18, 22, 35]. In addition,
transporters aid in clearing synaptically released glutamate to facilitate rapid high-fidelity
chemical communication between neurons [12, 38]. While glutamate transporters are
present on both neurons and glia, glial transporters are likely to mediate the bulk of
glutamate uptake [9]. Disruption in their functions could lead to such problems as
amyotrophic lateral sclerosis, Alzheimer's disease and neuronal death [25, 34].
The unitary turnover rate of transporters, i.e., the number of molecules that can be
transferred from the extracellular space across the membrane by a single transporter per
unit of time, is crucial for understanding of processes that shape synaptic transmission.
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The turnover rates reported in literature range from a few molecules per second on the
lower end [41, 43] to numbers that are several fold greater [4, 13]. The chemical blockage
of transporters is reported to rapidly elevate the ambient glutamate levels [7, 15, 18, 22,
35] and prolong glutamate receptor activation during synaptic transmission [1, 3, 26, 28,
36]. Paradoxically, the fastest turnover time constant of the predominant glutamate
transporter in the brain was estimated to be nearly two orders of magnitude slower than
the predicted time course of glutamate in the synapse [8, 37, 43]. It has been proposed
that buffering of glutamate by transporters, rather than actual uptake, plays an important
role in rapid lowering of neurotransmitter concentration during the first few milliseconds
of synaptic transmission [11, 13]. In this work we derive a model in order to reliably
estimate turnover rates of EAAT1-3 from experimental data. We also develop a model
combining spatial diffusion and transport that could help explain the sensitivity of
postsynaptic glutamate receptor responses to modulation of uptake despite low turnover
rates of transporters.
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Figure 1. Cartoon representation of neurons and a neuronal transmission (Wikimedia
Commons). Electrical impulses propagate down axon fibers and trigger release of
neurotransmitter filled vesicles (inset) that diffuse across the synapse to bind and activate
receptors on the postsynaptic cell. Astroglial cells (not shown) are variably interposed in
the spaces between neurons. Glutamate transporters EAAT1/2 are found predominantly
on glial cells and EAAT3 is expressed on neurons.
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2. EAATs CHEMICAL KINETICS MODELS
2.1. Existing models
EAATs transport glutamate against its electrochemical gradient using the
electrochemical gradients of other ions that are stoichiometrically coupled to glutamate
flux. With each molecule of glutamate 3 Na+ and 1 H+ are co-transported, and 1 K+ is
counter-transported [24, 44], i.e., the net charge of +2 moves into the cell with each full
cycle. This allows one to collect the data related to glutamate transport by recording the
charge movement in cells expressing the transporters in electrophysiology experiments.
The corresponding chemical kinetics model, depicted in Figure 2a, has been proposed
and studied, e.g., in [5, 21]. Glutamate transporters also play a role of a chloride channel
[41, 42], i.e., Cl− can permeate some states of the model depicted on Figure 2a resulting
in a net charge movement. The exact states that can interact in such a way with chloride
ions are not known. If we assume that this is possible for all states, this will increase the
number of states in the model to twice as many.
Unfortunately, the model is overparameterized with respect to the existing data
and, therefore, most individual reaction rate constants have statistically unreliable
estimates. It is possible to reduce the model under certain conditions during controlled
experiments in order to extract important physical properties of the transporters, such as
turnover rate. Let us consider an excised patch clamp type of experiment. A glass
micropipette with very fine opening on one end (∼1 μm in diameter) is gently pushed
against a single cell to form a tight seal with its membrane. Pulling the pipette causes
rupture and reseal of the small portion of the membrane on the tip of the glass tube, a
“patch”. Depending on the technique of pulling, the outer side of the membrane could
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either face the inside of the pipette (called “inside-out patch”) or the outside of the pipette
(called “outside-out patch”). The obtained patch retains the local structure of the cell
membrane, including transmembrane proteins like ion channels and transporters. The
solutions inside and outside of the micropipette are controlled by the investigator and
represent cytoplasm and extracellular fluid. The solution in the bath, i.e., outside of the
micropipette, can be rapidly switched by physically moving the pipette or bath. A piezo
electric switch is often used for such purposes and it allows for a solution change within
a few milliseconds. After the preparations one can study the flux of ions across the patch
using electrophysiology techniques, e.g., voltage clamp (the membrane potential is fixed
and the current that corresponds to the flow of ions is recorded). Since we have the total
control of the solutions that represent intracellular and extracellular space in excised
patch clamp experiments, let us adjust the ion concentrations in a such way that they
accelerate the transitions of the model states in a clockwise manner. That is, increase
sodium and hydrogen ions, and glutamate concentrations in the “extracellular space” to
saturate the transporters with them; at the same time we reduce the potassium ion
concentration in the “extracellular space” to facilitate K + unbinding from the transporter
state 𝑇 𝐾; and do the opposite for the “intracellular space”. The saturation of transporters
with substrates will effectively eliminate some states of the model due to almost
instantaneous binding of ligands to the transporters. Let us note that we are not
concerned that the concentrations of compounds in the solutions will change due to the
activity of transporters as the experiment goes on: the amount of molecules that can be
transferred across a small patch is negligible compared to their initial concentrations in a
time period it takes to perform the experiment. Under the described conditions the number
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of effective states in the model decreases to four. After addition of four more states that
are responsible for conductance of chloride ions, the reduced model is obtained; see
Figure 2b. Note that the model does not explicitly show concentrations of any compounds
because they can be assumed to be fixed over the duration of the experiment and are
included in the reaction rate constants. Similar models have been proposed and studied
before, see e.g., [6, 13, 27, 41]. Although these smaller models seem to retain many, if
not all, of the qualitative features of recorded currents, they still cannot be used for
parameter estimation as they remain to be overparameterized with respect to the
experimental data.
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Figure 2. EAAT chemical kinetics models. (a) 15-state model for EAATs. 𝑇 and 𝑇 stand
for transporter facing extracellular and intracellular spaces, respectively; Na, K, H denote
corresponding ions; G is L-glutamate; 𝑟 ± for all 𝑖 are reaction rate constants. 𝑟 and 𝑟
correspond to a clockwise and counterclockwise directions, respectively. (b) The
simplified 8-state model for the patch clamp experiment. The states with bars are the
corresponding conducting states, which allow the flow of chloride ions. (c) The chemical
kinetics scheme that corresponds to the reduced model (2.4).
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2.2. Reduced model
The chemical kinetics scheme depicted in Figure 2b can be represented by a
system of differential equations using the rate law. For each state we define a
corresponding variable, using the same notation, a fraction of all transporters observed
to be in this state (e.g., the variable 𝑇 (𝑡) is a portion of all transporters in 𝑇 state).The
system has the following form:
𝑑𝑇
= 𝑐 𝑇 − 𝑐 𝑇 − (𝑘 + 𝑘 )𝑇 + 𝑘 𝑇 𝐺 + 𝑘 𝑇 ,
𝑑𝑡
𝑑𝑇 𝐺
= −𝑐 𝑇 𝐺 + 𝑐 𝑇 𝐺 − (𝑘 + 𝑘 )𝑇 𝐺 + 𝑘 𝑇 + 𝑘 𝑇 𝐺,
𝑑𝑡
𝑑𝑇 𝐺
= −𝑐 𝑇 𝐺 + 𝑐 𝑇 𝐺 − (𝑘 + 𝑘 )𝑇 𝐺 + 𝑘 𝑇 𝐺,
𝑑𝑡
𝑑𝑇
= 𝑐 𝑇 −𝑐 𝑇 −𝑘 𝑇 +𝑘 𝑇𝐺+𝑘 𝑇 ,
𝑑𝑡

(2.1)

𝑑𝑇
= −𝑐 𝑇 + 𝑐 𝑇 ,
𝑑𝑡
𝑑𝑇 𝐺
= 𝑐 𝑇 𝐺 − 𝑐 𝑇 𝐺,
𝑑𝑡
𝑑𝑇 𝐺
= 𝑐 𝑇 𝐺 − 𝑐 𝑇 𝐺,
𝑑𝑡
𝑑𝑇
= −𝑐 𝑇 + 𝑐 𝑇 .
𝑑𝑡
During the experiments we will switch back and forth between the two bath
mixtures: one will contain glutamate, and another will not, with all other substances being
the same (see the next section for more details). All experiments start with no glutamate
in the bath, which corresponds to an extracellular space in the outside-out patch
experiments. The solution switch means an abrupt change in glutamate concentration. A
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transition of the transporter from 𝑇 state to 𝑇 𝐺 is impossible when the glutamate is
absent, therefore 𝑘 , the only coefficient that includes glutamate concentration, equals
zero. Effectively, this means that every time the bath mixture is changed, we will use the
end state of the system (2.1) with one value of 𝑘 as initial conditions for the system (2.1)
with another value of 𝑘 (where 𝑘 switches between a zero and a non-zero value). As
stated in the previous section, we cannot simply use the existing experimental data for
estimating model parameters due to overparameterization of system (2.1). Therefore,
some further model reduction is needed. According to [41], the transitions to conducting
states are much faster compared to the reactions which correspond to glutamate
transportation, i.e., 𝑐 ± ≫ 𝑘 ± for all 𝑖, 𝑗. We can define a small parameter 0 < ε < 1 in the
following way:
𝑐±
𝑐 =
,
ε
±

𝑐 ± ∼ 𝑂(1),

𝑘 ± ∼ 𝑂(1),

𝑖 = 1,4

(2.2).

The boundary function method [39] allows for the reduction of system (2.1). We represent
all the variables as asymptotic series with respect to the small parameter ε:
𝑣(𝑡) = 𝑣 (𝑡) + Π 𝑣(τ) + ε 𝑣 (𝑡) + Π 𝑣(τ) + ⋯,

(2.3)

where 𝑣(𝑡) represents any variable in the system (2.1) and τ = 𝑡/ε is a rescaled
(stretched) time variable. The terms in the asymptotic series that depend on 𝑡 are called
the regular functions, and the terms that depend on τ are called the boundary functions.
Next, we substitute (2.2) and (2.3) into the system (2.1). Equating coefficients of like
powers of ε, separately for regular and boundary layer functions, we obtain the reduced
model problems for different terms of the asymptotic expansion (2.3). The resulting
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system for the regular leading order approximation functions depends only on four
variables, which we denote as 𝑥(𝑡), 𝑦(𝑡), 𝑧(𝑡), and 𝑤(𝑡):
𝑑𝑥
= −𝑚 𝑥 + 𝑚 𝑦 + 𝑚 𝑤 − 𝑚 𝑥,
𝑑𝑡
𝑑𝑦
= 𝑚 𝑥 − 𝑚 𝑦 − 𝑚 𝑦 + 𝑚 𝑧,
𝑑𝑡

(2.4)

𝑑𝑧
= 𝑚 𝑦 − 𝑚 𝑧 − 𝑚 𝑧,
𝑑𝑡
𝑑𝑤
= 𝑚 𝑧 − 𝑚 𝑤 + 𝑚 𝑥,
𝑑𝑡
where
𝑚 =

𝑐 𝑘
,
𝑐 +𝑐

𝑚 =

𝑐 𝑘
,
𝑐 +𝑐

𝑚 =

𝑐 𝑘
,
𝑐 +𝑐

𝑚 =

𝑐 𝑘
,
𝑐 +𝑐

𝑚 =

𝑐 𝑘
,
𝑐 +𝑐

𝑚 =

𝑐 𝑘
,
𝑐 +𝑐

𝑚 =

𝑐 𝑘
.
𝑐 +𝑐

And all the functions of system (2.1) can be expressed through the functions of system
(2.4) in a certain way. If we allow the system to reach its steady state before the first bath
mixture change, then all the boundary layer functions will be identically zero and the
leading order approximations for the variables in (2.1) will contain only the corresponding
regular functions:
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𝑇 (𝑡) =

𝑐
𝑥(𝑡) + 𝑂(ε),
𝑐 +𝑐

𝑇 (𝑡) =

𝑐
𝑥(𝑡) + 𝑂(ε),
𝑐 +𝑐

𝑇 𝐺(𝑡) =

𝑐
𝑦(𝑡) + 𝑂(ε),
𝑐 +𝑐

𝑇 𝐺(𝑡) =

𝑇 𝐺(𝑡) =

𝑐
𝑧(𝑡) + 𝑂(ε),
𝑐 +𝑐

𝑇 𝐺(𝑡) =

𝑇 (𝑡) =

𝑐
𝑤(𝑡) + 𝑂(ε),
𝑐 +𝑐

𝑇 (𝑡) =

𝑐
𝑦(𝑡) + 𝑂(ε),
𝑐 +𝑐

(2.5)

𝑐
𝑧(𝑡) + 𝑂(ε),
𝑐 +𝑐

𝑐
𝑤(𝑡) + 𝑂(ε).
𝑐 +𝑐

The initial conditions for system (2.4) have the form:
𝑥(0) = 𝑇 (0) + 𝑇 (0),
𝑦(0) = 𝑇 𝐺(0) + 𝑇 𝐺(0),
𝑧(0) = 𝑇 𝐺(0) + 𝑇 𝐺(0),
𝑤(0) = 𝑇 (0) + 𝑇 (0).
As mentioned earlier, all the experiments will start without glutamate in the bath. Thus,
the initial conditions before the first switch correspond to the steady state in the absence
of glutamate (𝑘 = 0):
𝑥(0) =

𝑚
,
𝑚 +𝑚

𝑦(0) = 0,

(2.6)

𝑧(0) = 0,
𝑤(0) =

𝑚
.
𝑚 +𝑚

The sum of the variables entering system (2.4) is constant and it equals to the sum of all
the variables in system (2.1), which is 1. It is possible to draw a chemical kinetics scheme

65

that corresponds to the system (2.4) in the same manner as the scheme depicted in
Figure 2b relates to (2.1); see Figure 2c.
For each experiment the total current recorded during the experiment is a sum of
the stoichiometric current (coupled flux of glutamate molecules and ions across the
membrane), the conductive current due to the flow of chloride ions, and some constant
leak current [27, 41]. One might expect that during the transportation of one molecule of
glutamate +3 charge moves into the cell during the transition from state 𝑇 𝐺 to 𝑇 𝐺 (3 Na+,
H+, and Glu−) and +1 charge during the transition from 𝑇 𝐾 to 𝑇 (just K+). However, the
voltage–dependence of the transport suggests that the transporter also mediates a
capacitive charge transfer (gating charge movement).This means that, although the net
movement charge stays the same, actually the charge of +2 moves during the transition
from state 𝑇 𝐺 to 𝑇 𝐺 with all other transitions having no immediate effect on the
transportation current. The chloride-related current is proportional to the fractions of
transporters observed in the conductive states (𝑇 , 𝑇 𝐺, 𝑇 𝐺, and 𝑇 ). The resulting formula
for the total current is:
𝐼 = −𝐴 ⋅ 𝑇 − 𝐵 ⋅ 𝑇 𝐺 − 𝐶 ⋅ 𝑇 𝐺 − 𝐷 ⋅ 𝑇 − 𝐸(𝑘 𝑇 𝐺 − 𝑘 𝑇 𝐺) + 𝐼

.

Using (2.5), we can write the leading order approximation for the currentI0that depends
on 𝑥, 𝑦, 𝑧, and 𝑤. Since the system is in the steady state before the glutamate is
introduced for the first time, i.e., in the state (2.6), we can subtract the steady state current
in the above formula in order to identify the leading order approximation of the constant
value of 𝐼

. In order to further reduce the number of parameters, we can express any

one of the four variables in terms of the others since 𝑥(𝑡) + 𝑦(𝑡) + 𝑧(𝑡) + 𝑤(𝑡) = 1 for any
given instant of time 𝑡. We obtain the following formula:
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𝐼 (𝑡) = −𝒜 ⋅ 𝑥(𝑡) − ℬ ⋅ 𝑦(𝑡) − 𝒟 ⋅ 𝑤(𝑡) +

𝒜𝑚 + 𝒟𝑚
+ 𝑂(ε),
𝑚 +𝑚

(2.7)

where
𝒜=

ℬ=

𝑐 𝐴
𝑐 𝐶−𝑐 𝑘 𝐸
+
,
𝑐 +𝑐
𝑐 +𝑐

𝑐 𝐵+𝑐 𝑘 𝐸 𝑐 𝐶−𝑐 𝑘 𝐸
+
,
𝑐 +𝑐
𝑐 +𝑐

𝒟=

𝑐 𝐷
𝑐 𝐶−𝑐 𝑘 𝐸
+
.
𝑐 +𝑐
𝑐 +𝑐

Finally, the turnover rate of a particular transporter is equal to the influx of the
glutamate molecules through the transportation cycle in the steady state:
Θ = lim
→

=

𝑑𝐺
= lim 𝑘 𝑇 𝐺(𝑡)
→
𝑑𝑡

𝑘
𝑐 +𝑐
𝑐 +𝑐 𝑘
𝑐 +𝑐 𝑘 +𝑘
𝑐 +𝑐
𝑐 +𝑐 𝑘
+
+
+
+
𝑐
𝑐
𝑐
𝑘
𝑘
𝑐
𝑐
𝑘

𝑘 𝑘 +𝑘 𝑘 +𝑘 𝑘
𝑘 𝑘

Note, that although the concentrations of all the substrates are effectively constant for the
settings of the described experiment, the turnover rate implicitly depends on glutamate
concentration through the term 𝑘 . Corresponding leading order approximation in terms
of the parameters of the system (2.4) has the form:
Θ =

𝑚 𝑚 𝑚 𝑚
.
𝑚 𝑚 (𝑚 + 𝑚 ) + 𝑚 𝑚 (𝑚 + 𝑚 ) + (𝑚 + 𝑚 )(𝑚 𝑚 + 𝑚 𝑚 + 𝑚 𝑚 )
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(2.8)

2.3. Experiments and model fitting
Stage V–VI Xenopus oocytes were injected with mRNA encoding one of EAAT1–3. We
waited for 2–5 days to allow oocytes to express the transporters and excised outside-out
patches after removing a vitelline membrane. The solution inside the pipette, which
mimics intracellular space, contained 110 mM KCl, 3 mM MgCl 2, 5 mM Na-HEPES, and
10 mM EGTA. The bath solutions, which correspond to extracellular space, contained
110 mM NaCl, 3 mM MgCl2, 5 mM Na-HEPES, and 10mM or no glutamate. All solutions
were adjusted to pH 7.5 with Tris–base. Both bath mixtures flowed through a theta tube
that was mounted on and controlled by a piezo electric switch. The voltage clamp method
was used to record the flow of ions across the patch in a form of an electrical current, with
the recording electrode in the pipette and the ground electrode in the bath. The voltage
was fixed at −60 mV, which is close to a natural resting potential of neurons and
astrocytes. For more details of the voltage clamp technique see [41]. Each experiment
started with the patch exposed to a bath solution with no glutamate and was allowed to
stabilize and reach current steady state. After that we did a short rapid 50 ms step into a
solution with glutamate before switching back to the no-glutamate mixture. Then we
waited for a varied controlled amount of time (5, 10, 15, 20, 30, 40, 50, 60, 80, 100, 150,
200, 250, and 300 ms) and applied a second 30 ms step into the glutamate containing
solution. Note that the only differences between the experimental trials was a delay after
the first pulse. See Figure 3 for the representative data.

68

69

Figure 3. The currents recorded during the voltage clamp experiments in patches
expressing EAAT1. The time courses of glutamate application are depicted as step
functions above the actual data. Each application of the glutamate caused a spike of a
negative (inward) current that relaxed to a new steady state. After the termination of the
glutamate pulse, the system tended to its original steady state. The delays between the
pulses depicted here are 200, 80, 40, and 10 ms.
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The data for each transporter were fitted to model (2.4), (2.6), and (2.7) using delayed
rejection adaptive Metropolis Markov chain Monte Carlo (DRAM MCMC) method [14].
The fitting was done in MATLAB R2018a using MCMC toolbox. 1 The fitted model
solutions practically coincide with the experimental data for all cases, see Figure 4. The
algorithm yielded empirical confidence regions for the parameters; the resulting MCMC
chains were used for turnover rate estimates and inferences using the formula (2.8); see
Figures 5–7 for confidence regions and Table 1 of fitted parameter values.
The estimated value for EAAT1 turnover rate found here (15.45 s −1, 99%
confidence interval [15.31, 15.57]) is in agreement with previous studies: 16 molecules
per second in EAAT1 [41]. The estimate for EAAT2 turnover rate (23.96 s −1, 99%
confidence interval [11.94, 39.55]) is close to some previous studies, e.g., 14.6 molecules
per second in [43], while it is lower than ∼100 per second reported in [4]. The turnover
rate of EAAT3 was reported to be much higher: about 100 molecules per second [13],
compared to our estimate (1.98 s−1, 99% confidence interval [1.57, 2.36]).

1

MCMC toolbox for MATLAB by Marko Laine http://helios.fmi.fi/∼lainema/mcmc
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Figure 4. The currents recorded during the voltage clamp experiments in excised outsideout patches fitted to the model. Top row depicts all the data for the corresponding
transporter combined (left to right: EAAT1, EAAT2, EAAT3). All recorded pairs of pulses
like the ones in Figure 3 were overlapped and the first pulses being almost identical. With
the first pulse being fixed, it is easy to see the change in the dynamics of the second
pulses, e.g., note how the peaks of the second pulses deteriorate but recover as the delay
between the pulses increases. The second row shows the same data (now in gray) fitted
using the model (black curves).
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Figure 5. 95% and 99% confidence regions (inner and outer contours, respectively) for
the model of EAAT1 yielded by the MCMC method. The last picture shows the distribution
of EAAT1 turnover rate with the median value of 15.45 s−1, 99% confidence interval:
[15.31,15.57].
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Figure 6. Similar results are shown for EAAT2. The median turnover rate value is
estimated 23.96 s−1, 99% confidence interval: [11.94,39.55].
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Figure 7. Similar results are shown for EAAT3. The estimated EAAT3 turnover rate of
1.98 s−1, 99% confidence interval: [1.57,2.36], was unexpectedly small compared to
hundreds of molecules per second reported in other literature.
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Table 1. All units are s−1.

EAAT1

EAAT2

EAAT3

Median

95% CI

Median

95% CI

Median

95% CI

𝑚

1038.65

[1037.84; 1040.75]

1155.84

[891.92; 1380.94]

510.72

[501.70; 520.70]

𝑚

0.03

[0.00; 0.13]

101.99

[12.78; 288.26]

97.10

[96.12; 98.33]

𝑚

111.25

[110.10; 112.34]

556.67

[413.85; 837.91]

72.22

[70.05; 74.70]

𝑚

106.11

[102.67; 109.11]

697.34

[359.99; 918.31]

373.72

[362.31; 382.82]

𝑚

287.23

[285.15; 289.68]

422.36

[142.80; 1027.13]

16.50

[14.39; 18.38]

𝑚

22.10

[21.93; 22.25]

31.12

[18.63; 45.44]

21.34

[20.09; 22.45]

𝑚

61.90

[61.64; 62.17]

13.35

[1.68; 28.93]

2.51

[2.10; 2.90]

𝐴

665.24

[664.28; 666.78]

167.29

[97.69; 266.50]

374.54

[353.05; 390.47]

𝐵

1339.80

[1338.44; 1342.64]

265.48

[196.36; 425.29]

458.20

[436.92; 474.26]

𝐷

656.43

[654.81; 661.03]

163.93

[94.32; 263.25]

-15.56

[−26.69;−3.76]
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3. DIFFUSION MODEL
EAAT turnover rates estimated here and in the other published studies are
significantly slower than the estimated time course of glutamate in the synaptic cleft [8,
37]. Nevertheless, the application of the glutamate transporter competitive antagonist DLthreo-benzyloxyaspartic acid (TBOA) to hippocampal slices were reported to rapidly
elevate the ambient glutamate levels [7, 15, 18, 22, 35]. Moreover, the application of
EAATs’ blockers appears to prolong glutamate receptor activation during synaptic
transmission [1, 3, 26, 28, 36]. While rise in ambient glutamate level is possible for any
turnover rate given high enough density, the estimated EAATs concentrations in the
synaptic cleft are too low to account for sufficiently fast changes that could reshape
synaptic transmission [9]. It has been suggested that the initial fast phase of glutamate
removal is due to diffusion and buffering effect of transporters rather than the transport of
neurotransmitter [10, 43]. This buffering would require a relatively long lasting binding of
glutamate molecule to the transporter [13, 23]. It is worth noting that the data with
prolongation of the receptor activation during synaptic transmission by blockers
correspond to a whole cell or multiple cells rather than a single synapse [1, 3, 26, 28, 36].
Since the application of blockers raises ambient glutamate level which activates
extrasynaptic receptors [22], it might play a significant role in apparent synaptic
prolongation. In order to understand the relative contribution of transport and diffusion to
dynamics of glutamate we created a simple spatial model of a single synapse, described
below. We note that other approaches, e.g., Monte Carlo simulations, are also used for
the analysis of neurotransmitter dynamics in a synaptic cleft; see, e.g., [32, 33].
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Let us represent a synaptic cleft as a circular cylinder, with bases being pre- and
postsynaptic cell surfaces, then we can describe the glutamate dynamics by a diffusion
model. Upon arrival of an action potential, voltage-gated calcium channels in the
presynaptic cell axon terminal transiently open, resulting in a brief elevation of intracellular
calcium and release of glutamate stored in intracellular vesicles. This release is mediated
by a specialized region on a presynaptic cell, called the active zone, which contains
protein that mediate calcium-dependent vesicle fusion with the axon terminal membrane.
The neurotransmitter diffuses across the synaptic cleft and reaches receptors on the
postsynaptic cell, located in the region called the postsynaptic density (PSD). We assume
that the active zone and PSD have a circular shape with their centers coinciding with the
corresponding cylinder base centers. EAATs play an important role in removing glutamate
from the synaptic cleft to terminate the signal and allow an effective information
transduction between the cells as well as limit its negative effects (e.g., excitotoxicity).
Some of EAATs are expressed in a synaptic cleft, while others are found on astrocytes:
EAAT3 are exclusively expressed on neurons’ in dendrites and somas and EAAT1 are
found on astrocytes. EAAT2 are expressed on both astrocytes and synapses of
presynaptic cells, although EAAT2’s expression in synapses is about 10 times lower [9,
17]. We assume that the distribution of EAATs is uniform where they are present. About
50% of the synapses in rat hippocampus region CA1 are enveloped by astrocytes and
they are surrounded only partially [40]. This means that glutamate can escape synapse
by either facilitated transport or free diffusion to the space outside the synapse. The latter
is called a spillover and can lead to activation of neighboring synapses [40]. The model
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describes a single synapse, so we also assume no glutamate spillover from other
synapses. See Figure 8 for a visual representation.
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Figure 8. A cartoon representation of the synapse. The presynaptic cell contains vesicles
with glutamate that enter synaptic cleft through active zone (inner circle), diffuse towards
the post-synaptic cell and are sensed by receptors located in the postsynaptic density
(inner circle). Astrocyte envelops the cleft to some degree that varies from synapse to
synapse. EAAT1–2 transporters are located on the astrocyte facing the synapse. EAAT2
also found in the cleft on the presynaptic cell outside of the active zone with expression
~10 times lower compared to the one in astrocytes. EAAT3 are expressed on the
postsynaptic cell outside of the postsynaptic density.
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It is convenient to write a diffusion equation in cylindrical coordinates:
∂𝑢
1 ∂ ∂𝑢
1∂ 𝑢 ∂ 𝑢
=𝐷
𝑟
+
+
,
∂𝑡
𝑟 ∂𝑟 ∂𝑟
𝑟 ∂θ
∂𝑧

(3.1)

𝑡 ≥ 0, 0 < 𝑟 ≤ 𝑅, 0 ≤ θ < 2π, 0 ≤ 𝑧 ≤ 𝐿,
where 𝑢(𝑡, 𝑟, θ, 𝑧) is a concentration of glutamate at a time 𝑡, at a radial distance 𝑟, angular
coordinate θ and height 𝑧; 𝐷 = 0.4μ𝑚 𝑚𝑠

is the diffusion coefficient of glutamate in a

synaptic cleft, which is about half of that in a free medium [29, 32, 45]; 𝑅 = 150𝑛𝑚 is the
radius of a synaptic cleft [32, 40]; 𝐿 = 20𝑛𝑚 is the width of a synaptic cleft [32]. Let us
note, that for 𝑟 = 0, the equation (3.1) can be rewritten in Cartesian coordinates at the
origin. The boundary conditions are:
𝜕𝑢
𝐷
𝜕𝑧

𝜕𝑢
−𝐷
𝜕𝑧

0,
=

𝑁𝑉

0 ≤ 𝑟 ≤ 𝑟 , ∀θ,
𝑢(𝑡, 𝑟, θ, 0)
𝐾

( )

+ 𝑢(𝑡, 𝑟, θ, 0)

−

𝑢
𝐾

( )

,

+𝑢

0,
=

𝑁𝑉

𝑟 < 𝑟 ≤ 𝑅, ∀𝜃,

(3.2)

0 ≤ 𝑟 ≤ 𝑟 , ∀𝜃
𝑢(𝑡, 𝑟, 𝜃, 𝐿)
𝐾

( )

+ 𝑢(𝑡, 𝑟, 𝜃, 𝐿)

−

𝑢
𝐾

( )

,

+𝑢

𝑟 < 𝑟 ≤ 𝑅, ∀𝜃

The last boundary condition is:
−𝐷

∂𝑢
∂𝑟

=

𝑁 𝑉

𝑢(𝑡, 𝑅, θ, 𝑧)
𝐾

( )

+ 𝑢(𝑡, 𝑅, θ, 𝑧)

−

𝑢
𝐾

( )

+𝑢

,

(3.3)

0 ≤ 𝑧 ≤ 𝐿, 0 ≤ 𝜃 < 2 𝜋𝜌,
for the proportion of synapse covered by astrocyte, defined by the parameter 0 ≤ ρ ≤ 1,
and
𝑢(𝑡, 𝑅, θ, 𝑧) = 𝑢 ,

2πρ ≤ θ < 2π.

(3.4)

Here 𝑢 = 25𝑛𝑀 is an ambient glutamate level [7, 15, 18, 22, 35]; 𝑟 = 100𝑛𝑚 is a radius
of an active zone [31]; 𝑟 = 100𝑛𝑚 is a radius of a postsynaptic density [32, 40]; 𝑁 =
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2300𝜇𝑚 , 𝑁 = 750𝜇𝑚 , 𝑁 = 7500𝜇𝑚 , and 𝑁 = 90𝜇𝑚

are densities of EAAT1,

EAAT2 on axon terminals, EAAT2 on astrocytes, EAAT3, respectively [9, 17]; 𝑉 =
1.542 × 10 𝑚𝑠

, 𝑉 = 2.396 × 10 𝑚𝑠

, and 𝑉 = 0.198 × 10 𝑚𝑠

are EAAT1–3

turnover rates, respectively. Glutamate uptake by the transporters is described by
Michaelis-Menten kinetics with 𝐾

( )

= 20μ𝑀, 𝐾

( )

= 18μ𝑀, and 𝐾

( )

= 28μ𝑀 constant for

EAAT1–3, respectively [2, 9]. We note that the transporters are located on the surface of
neurons and on the surface of an astrocyte, and for this reason the appearance of
Michaelis-Menten kinetics in the boundary conditions is appropriate. The corresponding
kinetics reactions take place in a thin layer near the boundary, and the boundary
conditions (3.2), (3.3) are obtained by averaging of the processes taking place in the
volume of the layer over the layer’s thickness. The surface concentrations of the
transporters are reported in the literature together with corresponding Michaelis-Menten
constants values (see the numbers presented earlier). The averaging of the transporter
concentrations over the height of the synaptic cleft as well as inclusion of MichaelisMenten kinetics as a reaction term in the diffusion equation may also be performed under
certain conditions (see, [19, 20] for further discussion). The astrocytes facilitate glutamate
uptake and serve as a physical barrier to prevent a spillover. Due to complex brain
environment the concentration of glutamate in the proximity of the synapse could vary,
so the boundary condition (3.4) may not be adequate at all times. But since we are not
considering a spillover phenomenon here, we assume it to be true. Let us note that not
every action potential in a presynaptic cell causes the release of even a single vesicle
[16, 40], which contain about 3000 molecules [30, 32]. To conservatively estimate the
clearance of a synaptic cleft from the glutamate, we assume that exactly one vesicle is
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released on each stimulation from the center of the active zone. Thus, the initial conditions
are
𝑢(0, 𝑟, θ, 𝑧) = 3000 ⋅ δ(𝑟 cos θ) ⋅ δ(𝑟 sin θ) ⋅ δ(𝑧) + 𝑤(𝑟, θ, 𝑧),

(3.5)

where δ(⋅) is the Dirac delta function and 𝑤 is a state of the system before the pulse.
𝑤(𝑟, θ, 𝑧) = 𝑢

for the first stimulation and for all consecutive ones 𝑤(𝑟, θ, 𝑧) is equal to

the end state of the model at the previous step.
We are interested in the dynamics of glutamate concentration on the surface of the
PSD of the postsynaptic cell: the time it takes the glutamate to reach the receptors, how
long the concentration stays high, how fast the glutamate gets cleared out from the cell
surface to allow for adequate reaction to the consecutive signals. We used finite
difference approximation for the derivatives in the right-hand side of equation (3.1) and
boundary conditions (3.2)–(3.3). Then, we numerically solved the resulting system of
differential equations using MATLABR2018a built-in solver ode15s. That allowed us to
have an adaptive time step, which was desirable: the experimental data clearly show
relatively fast and slow dynamics. The spatial grid used for the finite difference derivative
approximation

was

the

following: 𝑟 = 𝑖 ⋅ Δ𝑟

𝑖 = 0,30, Δ𝑟 = 5𝑛𝑚 ;

𝜃 = 𝑗 ⋅ Δ𝜃

𝑗 = 0,29, Δ𝜃 = 𝜋/15 ; 𝑧 = 𝑘 ⋅ Δ𝑧 𝑘 = 0,4, Δ𝑧 = 5𝑛𝑚 . The simulations are depicted in
Figure 9. Each vesicle release causes a sharp spike of glutamate concentration on the
dendrite surface, which rapidly decays on a scale of a millisecond. The shape of the curve
changes with the proportion ρ of the synapse covered by an astrocyte. In the case when
high frequency stimulation (100 Hz) was applied, the glutamate was cleared from the
synaptic cleft between pulses even when ρ > 0.9. Only when the synapse was completely
covered by the astrocyte the solution drastically changed its behavior. In all the other
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cases the simulated time course of the glutamate simulated here was consistent with the
experimental measurements reported in the literature [8, 37]. However, let us note that it
is unlikely that even a full astrocyte coverage of a synapse would be tightly sealed in
reality [40]. We found that the change in EAAT3 turnover rate from about 2s −1 to 110s−1
(value reported in [13], data not shown) did not bear any noticeable effect due to the
transporter low expression: only few transporters per synapse of a size modeled here,
which in fact might be even lower [9]. The simulation of transporter blockage, i.e., setting
the turnover rate of transporters to zero and rising the ambient glutamate level 𝑢 to the
reported value [7, 18, 22], does not yield any significant change in the glutamate dynamics
in the synaptic cleft. Therefore, we conclude that the blockage of the transporters could
not significantly prolong the activation of synaptic glutamate receptors in an individual
synapse.
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Figure 9. The dynamics of the average glutamate concentrations on the surface of the
post-synaptic density “PSD” according to the diffusion model. Top left. Results of a
release of a single vesicle into the synaptic cleft with an astrocyte covering various
portions of the synapse. The corresponding parameter values of ρ are 0 (fastest decay),
0.3, 0.6, 0.9, and 1 (slowest decay). When the astrocyte covers the synapse fully (ρ = 1)
it takes much longer for the glutamate concentration to reach its steady state value 𝑢
(see also bottom left).Top right. Series of 5 high-frequency vesicle releases (100 Hz) with
almost complete astrocytic envelopment (ρ = 0.95). Glutamate is cleared from the
synaptic cleft and does not accumulate between the pulses. Bottom left. Series of 3 highfrequency vesicle releases (100 Hz) with complete astrocytic coverage (ρ = 1).
Glutamate accumulates between the pulses and requires much longer time (almost 1s
here) to clear from the synaptic cleft via facilitated transport by EAATs. The inset graph
shows the first 25ms of the same plot that includes all three pulses. Bottom right. The
modeling of transporter blockage in case ρ = 0.95. The solid line represents the normal
timecourse of glutamate (i.e., same as a single pulse from top right graph), the dashed
line corresponds to the blockage case. The difference is almost impossible to see; hence
the inset shows a zoomed portion of the same plot (note the axes scale).
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3. CONCLUSION
EAATs actively remove glutamate from the extracellular space with an efficient ion
gradient-coupling mechanism and the equilibrium thermodynamics of this transport
mechanism result in nanomolar ambient levels that limit receptor activity over long time
scales (for review see [35]). On the shorter time scales of pulsatile synaptic signaling, the
kinetic properties of the transporters, such as the binding rates and turnover rates, are
expected to influence the role transporters play in shaping the millisecond-scale time
course of synaptically released glutamate. Estimates of these kinetic parameters vary in
the literature [4, 13, 41, 43]. A precise understanding of these non-equilibrium kinetic
parameters is important for understanding the role of transporters in shaping the
dynamics of synaptic transmission. Here we used previously established chemical
kinetics models of EAAT1–3 [5, 6, 13, 21, 27, 41] and derived a new model, the purpose
of which was to avoid overparameterization problems in constraining turnover rates. The
experiments were designed alongside the model to allow for such reduction. We used the
model to fit experimental transporter data and estimate turnover rates of EAAT1–3. The
values obtained for EAAT1–2 are in agreement with previous studies that used
independent approaches [41, 43]. The turnover rate estimate obtained for EAAT3 in the
present work was found to be about 100-fold lower than existing estimates [13]. In that
study authors used a similar 6-state model to estimate turnover rate. Possible reasons
for the discrepancy in estimates include overparameterization issues in the latter study.
In any event, the overall effect of EAAT3 on synaptic transmission is expected to be
smaller compared to the other transporter subtypes due to its lower density in brain [9]
(but see [10]).
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It is well-established that over longer time scales, transporters maintain low
ambient glutamate levels, which rapidly rise upon pharmacological block [7, 15, 18, 22,
35]. We constructed a 3D diffusion model of a single synapse using estimated EAATs
turnover rates and densities in order to formalize a simple proof of concept about the role
of transporters at a single independent synapse. Our model simulation of the time course
of glutamate in the synaptic cleft is in good accordance with prior estimates [8, 37]. Our
findings support the idea that the rapid glutamate concentration rise and peak decay in
the proximity of the postsynaptic receptors are achieved by the physical properties of the
cleft itself, rather than active transport the transporters. According to the model, unless
the synapse is completely sealed by an astrocyte, EAATs are not playing any significant
role in removing synaptically released glutamate. This is not surprising, considering that
time it takes for EAATs to transport one molecule of glutamate is several folds longer than
the time the glutamate is present in the synapse at high concentrations. Although EAATs
play a crucial role in controlling ambient glutamate levels, it is unlikely that EAATs shape
the time course of synaptically released glutamate on the scale of a single synapse. A
number of studies report that the pharmacological block of glutamate transporters
prolongs receptor activation during synaptic transmission [1, 3, 26, 28, 36]. However, the
data collected in these studies are on a scale of many synapses, or synapses with multiple
release sites, which introduces additional phenomena, in particular pooling and
heterosynaptic interactions that are not considered here. The results reported here are
consistent with the idea that on the millisecond time scale of synaptic release, the role of
transporters exclusively involves limiting activation of extrasynaptic receptors by spillover
phenomena involving interaction of multiple synapses.
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ABSTRACT
Accurate knowledge of the ambient extracellular glutamate concentration in
brain is required for understanding its potential impacts on tonic and phasic receptor
signaling. Estimates of ambient glutamate based on microdialysis measurements are
generally in the range of ~2–10μM, approximately 100-fold higher than estimates
based on electrophysiological measurements of tonic NMDA receptor activity (~25–
90nM). The latter estimates are closer to the low nanomolar estimated thermodynamic
limit of glutamate transporters. The reasons for this discrepancy are not known, but it
has been suggested that microdialysis measurements could overestimate ambient
extracellular glutamate because of reduced glutamate transporter activity in a region
of metabolically impaired neuropil adjacent to the dialysis probe. We explored this
issue by measuring diffusion gradients created by varying membrane densities of
glutamate transporters expressed in Xenopus oocytes. With free diffusion from a
pseudo-infinite 10μM glutamate source, the surface concentration of glutamate
depended on transporter density and was reduced over 2 orders of magnitude by
transporters expressed at membrane densities similar to those previously reported in
hippocampus. We created a diffusion model to simulate the effect of transport
impairment on microdialysis measurements with boundary conditions corresponding
to a 100 μm radius probe. A gradient of metabolic disruption in a thin (~100 μm) region
of neuropil adjacent to the probe increased predicted [Glu] in the dialysate over 100fold. The results provide support for electrophysiological estimates of submicromolar
ambient extracellular [Glu] in brain and provide a possible explanation for the higher
values reported using microdialysis approaches.
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1. INTRODUCTION
During synaptic transmission, glutamate transporters restrict the spatiotemporal
pattern of ionotropic and metabotropic glutamate receptor signaling (for review see
Tzingounis and Wadiche, 2007). In addition to their roles in shaping the dynamics of
synaptically released glutamate, glutamate transporters also help maintain low steadystate glutamate levels. Given the stoichiometry of ion coupling to glutamate uptake, the
theoretical lower limit of extracellular glutamate in brain is approximately 2 nM (Zerangue
and Kavanaugh, 1996; Levy et al., 1998). Many studies using intracerebral microdialysis
have reported levels of ambient glutamate ≥2 μM, three orders of magnitude higher than
the theoretical lower limit (Benveniste et al., 1984; Lerma et al.,1986; for reviews see
Cavelier et al., 2005; Nyitrai et al., 2006). By contrast, reports of ambient glutamate
concentration estimated from electrophysiological measurement of tonic NMDA receptor
activity in hippocampal slice range from 87 to 89 nM (Cavelier and Attwell, 2005; Le Meur
et al., 2007) to as low as 25 nM (Herman and Jahr, 2007).
Accurate knowledge of the ambient glutamate concentration in different brain
regions is important for evaluating its effects on synaptic transmission. Several ionotropic
and metabotropic glutamate receptor subtypes are activated by low micromolar
concentrations of glutamate, and tonic exposure in this range profoundly inhibits synaptic
circuitry in vitro (Zorumski et al.,1996). Glutamate transporters play a dominant role in
limiting ambient glutamate, as pharmacological inhibition of transport has been shown to
lead to a rapid increase in ambient glutamate causing increased tonic NMDA receptor
signaling (Jabaudonet al., 1999; Cavelier and Attwell, 2005; Le Meur et al., 2007;Herman
and Jahr, 2007).
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In this work we attempt to integrate data in the literature with new in vitro
measurements and modeling of diffusion gradients formed by glutamate transporters.
Proceeding from the assumption that in steady-state conditions, the volume-averaged
rates of release and uptake of glutamate are equal, we show the influence of glutamate
transporter membrane density on steady-state diffusion gradients in a density range
relevant to in vivo brain expression. We suggest that metabolic impairment of glutamate
transport in a shallow boundary region of a microdialysis probe can account for the
discrepancies

between

estimates

of

ambient

electrophysiological approaches.
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2. MATERIALS AND METHODS
2.1. Xenopus oocyte recording
Approximately 50 ng of human EAAT3 cRNA was microinjected into stage V–VI
Xenopus oocytes and recordings were made 1–6 d later. Recording solution contained
96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM Hepes (pH 7.5).
Microelectrodes were pulled to resistances between 1 and 3 MΩ and filled with 3 M KCl.
Data were recorded with Molecular Devices amplifiers and analog–digital converters
interfaced to Macintosh computers. Data were analyzed offline with Axograph X (v.1.0.8)
and Kaleida-Graph (v 3.6; Synergy) software. For stopped flow measurements, oocytes
were voltage clamped at -60mV in a perspex recording chamber in which glutamate
depletion in the absence of perfusion was <1% of the total in the recording chamber.
Transporter surface density was estimated from current measurements assuming a
coupled current of 2 charges/cycle at ECl (-20 mV), turnover rate of 15/s, oocyte surface
area 2.85×107 μm2, and transport volt-age-dependence of e-fold/76 mV (Wadiche et al.,
1995; Zerangue and Kavanaugh, 1996). Current amplitudes were fitted to the Michaelis–
Menten relationship:

𝐼[

]

=𝐼

[𝐺𝑙𝑢]/{𝐾 + [𝐺𝑙𝑢]}.

2.2. Mathematical modeling of [Glu] profile near the microdialysis probe
Our microdialysis probe model can be described by the following diffusion equation
in polar coordinates with sink and source in the right-hand side:

∂𝑢
= 𝐷 ⋅ (1/𝑟) ⋅ ∂/ ∂𝑟[𝑟 ⋅ ∂𝑢/ ∂𝑟] − 𝐽 ⋅ 𝑢/(𝐾 + 𝑢) + 𝐾 ,
∂𝑡
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where 𝑢 corresponds to L-glutamate concentration. The first term in the right-hand side
is a Laplace operator in polar coordinates multiplied by a diffusion coefficient 𝐷 . The
second term representsthe Michaelis–Menten transport sink in the tissue, and the third
term 𝐾 represents the leak, which is treated as a constant. The parameter 𝐽 is a function
of distance 𝑟 from the probe center, and describes the spatial dependence of transporter
impairment between the healthy and damaged tissue. The spatial metabolic damage near
the probe is approximated as a Gaussian curve, and we define the function 𝐽 as:

𝐽(𝑟) =

𝐽

0,
⋅ 1 − 𝑒^[−(𝑟 − 𝐿) /2 ⋅ 𝑠𝑖𝑔𝑚𝑎 ],

0 ≤ 𝑟 ≤ 𝐿,
𝑟 > 𝐿,

where 𝐿 is the radial boundary for the microdialysis probe andsigma represents the
distance from the probe boundary character-izing the Gaussian damage function. The
boundary conditions for the model are:

∂𝑢/ ∂𝑟|

= 0,

𝑢(𝑡, ∞) = 𝑢 .
The initial condition is

𝑢(𝑡, 𝑟) =

𝑢∗ ,
𝑢 ,

0 ≤ 𝑟 < 𝐿,
𝑟 > 𝐿.

This model cannot be solved analytically because of the nonlinear term in the righthand side of the equation, so it was solved numerically by space discretization, which
transforms it into system of ordinary differential equations. The leak rate constant (𝐾 ) is
related to ambient [Glu], volumetric glutamate transporter concentration [GluT] (140 μM,
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Lehre and Danbolt, 1998), transporter 𝐾 value, and maximal turnover rate 𝐽
equation:

𝐾 = [𝐺𝑙𝑢]

/(𝐾 + [𝐺𝑙𝑢]
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) ⋅ [𝐺𝑙𝑢𝑇] ⋅ 𝐽

.

by the

3. RESULTS
3.1. Diffusive concentration gradients formed by glutamate transporters
Co-expression studies of NMDA receptors with transporters for its coagonists glycine and
glutamate have shown that transporters can limit receptor activity by establishing
diffusion-limited transmitter concentration gradients (Supplisson and Bergman, 1997; Zuo
and Fang, 2005). We studied the concentration gradients formed by passive diffusion
from a pseudo-infinite glutamate source in a perspex chamber to the glutamate sink
established by transporters on the cell surface. Oocytes expressing the human neuronal
glutamate transporter EAAT3 were voltage-clamped at -60 mV and superfused with
varying concentrations of glutamate at a linear flow rate of 20 mm/s flow followed by a
stopped-flow interval (Fig. 1). Steady-state currents elicited by glutamate perfusion
relaxed to a lower steady-state level when flow was stopped, and following resumption of
flow, currents rapidly recovered to initial values. The reduction in current amplitude during
zero flow conditions was likely due to the formation of a diffusion-limited concentration
gradient resulting in reduced surface [Glu], because the ratio of the current amplitudes
with and without flow were dependent on the concentration of glutamate in the perfusate,
and in all cases the amount of glutamate transported was <1% of the total glutamate in
the chamber (i.e., a pseudo-infinite glutamate source; Fig. 1B–D). This gradient was also
reflected in a significant shift in the concentration-dependence of steady-state currents in
flow and stopped-flow conditions (𝐾

value for L-glutamate of 32 ± 2 and 216 ± 37 μM,

respectively, n=4; p< 0.002), while the 𝐼

values were not significantly different.
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Fig. 1. Glutamate transport acts as a sink to form a concentration gradient between the
extracellular volume and the membrane surface. (A) Current induced by 10 μM glutamate
decays to a lower steady state flow under stopped-flow conditions at -60 mV. (B) Current
responses to varying [Glu] with and without flow at -60 mV. (C) Glutamate concentrationdependence of steady-state currents in flow and stopped-flow conditions. ( 𝐾 value with
flow: 32 ± 2 μM; stopped-flow: 215 ± 37 μM; n=4, p=0.0014). (D) Glutamate concentrationdependence of the ratio of current amplitudes in stopped-flow and flow conditions.
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3.2. Transporter density influence on kinetic parameters
Glutamate transporters are expressed at different densities among structures in
the CNS, and transporter density and/or kinetics can be altered in different pathological
circumstances such as trauma and ischemia. Because steady-state ambient [Glu] reflects
a homeostatic balance of uptake and leak sources, changes in transport may result in
significantly different steady state glutamate levels. We tested the influence of the surface
density of glutamate transporters on the concentration gradient formed by passive
glutamate diffusion during stopped-flow experiments by monitoring currents induced by
10μM glutamate. With increasing transporter expression levels, the steepness of the
concentration gradient formed during stopped-flow conditions was increased, as reflected
in the changing ratio of the steady-state currents in flow and stopped-flow conditions (Fig.
2A and B).
Even with continuous flow, evidence for formation of a concentration gradient
between the cell surface and bulk solution was observed. Oocyte membranes have a
microvillar structure that can act as tortuous diffusion barrier (see Supplisson and
Bergman, 1997). In a group of 29 oocytes with varying expression levels, steady-state

𝐾 values measured with chamber flow (20 mm/s) increased approximately 4-fold as
transporter current induced by 1 mM glutamate increased from ~200 to ~1100 nA (Fig.
2C and D). Thus, there is an effect of the concentration gradient formed by transporters
even with continuous flow, resulting in a discrepancy between the measured and actual
glutamate 𝐾

value. We extrapolated a linear function relating the measured 𝐾

value

to the transport current density (Barry and Diamond,1984), yielding an estimate of the
intrinsic 𝐾 value of approximately 27 μM (r= 0.78; Fig. 2D).
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Fig. 2. Glutamate concentration gradients are a function of transporter density. (A)
Representative traces of stopped-flow experiments with oocytes expressing different
transporter densities. (B) Currents from cells in (A) normalized to the steady state current.
(C) Glutamate concentration-dependence of steady-state currents with low, medium and
high expression levels. (𝐾

values: low expression: 33 μM, medium expression: 50 μM

and high expression: 98 μM. Transport current amplitudes (1 mM glutamate) are 260, 332
and 688 nA, respectively). (D), 𝐾 values from 29 oocytes with different expression levels
(fitted with linear regression, r= 0.78; y intercept = 26.8 μM).
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3.3. Surface [Glu] as a function of transporter density
While the dependence of steady-state 𝐾

on transporter density reflects the fact

that the true glutamate concentration at the cell surface is reduced by uptake, the
concentration difference associated with the diffusion gradient is minimal when high
concentrations of glutamate are applied by continuous flow. In oocytes expressing varying
densities of transporters, we recorded currents induced by superfusion of 1 mM glutamate
in order to generate the theoretically predicted current amplitude in each cell as a function
of [Glu] from the Michaelis–Menten function using the intrinsic 𝐾

value of 27 μM (Fig.

3A). We then recorded the actual steady-state current amplitude in each cell in response
to 10 μM glutamate under stopped-flow conditions and compared these to the values
predicted by the Michaelis–Menten function. There was a discrepancy between the
theoretically predicted and measured values, and this difference increased monotonically
with transporter density. We inferred the actual glutamate surface concentration in the
stopped-flow condition with 10 μM glutamate in the chamber from the measured current
amplitudes using the uniquely determined Michaelis–Menten function for each cell (Fig.
3A and inset). The inferred surface concentration was then plotted as a function of
transporter density. There was a supralinear effect of transporter density on surface [Glu]
in stopped-flow conditions (Fig. 3B). Transporter density in this group of cells ranged from
234 to 5165 transporters per μm2. At low expression levels, the estimated [Glu]
approached the 10 μM source concentration. However, at transporter densities of ~5000
per μm2 (compare with estimates in hippocampus of 10,800 μm 2; Lehre and Danbolt,
1998), surface [Glu] was estimated to be reduced to ~50 nM, roughly 200-fold lower.
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Fig. 3. Surface [Glu] estimates as a function of transporter density. Surface [Glu]
estimated from relative amplitude of steady state current amplitude without flow to the 1
mM steady state glutamate current with flow fitted to Michaelis–Menten function (𝐾

=

26.8 μM) (A, semi-log plot; inset, double-log plot) and plotted as a function of transporter
density (B) for each oocyte at -60 mV.
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3.4. Modeling the glutamate concentration profile near a microdialysis probe
We constructed a diffusion model to simulate the spatial profile of glutamate near
a microdialysis probe (see Section 2). From quantitative immunoblotting, the glutamate
transporter density in hippocampus has been estimated to be between 0.14 and 0.25 mM
(Lehre and Danbolt, 1998). From the transporter density, glutamate transport averaged
over a given volume of neuropil can be estimated for any given ambient glutamate value
based on Michaelis–Menten kinetics (neglecting exchange, which becomes significant
near the equilibrium thermodynamic limit). At steady state, sources and sinks are equal,
and the steady-state leak and uptake of glutamate are equal. With ambient [Glu] = 25 nM
(Herman and Jahr, 2007) and using the lower transporter density estimate of 0.14 mM
(Lehre and Danbolt, 1998), the volume-averaged steady-state glutamate leak is predicted
to be approximately 2100 molecules μm-3 sec-1 (but see Cavelier and Attwell, 2005).This
tonic leak will cause increased ambient glutamate if transport is reduced, as could occur
in a metabolically impaired region of neuropil near a microdialysis probe (Benveniste et
al., 1987; Clapp-Lilly et al., 1999; Amina et al., 2003; Bungay et al., 2003; Jaquins-Gerstl
and Michael, 2009). We used the diffusion model to describe the spatial profile of [Glu]
near a 100 μm radius microdialysis probe with an adjacent damaged region described by
a Gaussian gradient of impaired transport (Fig. 4A). Although transporter reversal can
occur with severely impaired ion gradients, we neglected this effect, which may
underestimate effects of metabolic damage on glutamate measured in the probe. Starting
the simulation at time = 0 with no glutamate in the interior of the probe, the glutamate
concentration rises with an exponential time constant ~8.5 s to a steady state level (data
not shown). At steady state, [Glu] inside the probe is elevated relative to the healthy region
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far from the probe (Fig. 4B1). With sigma = 0 (i.e. no tissue damage), [Glu] in the probe is
equal to the ambient [Glu] in the healthy tissue. With gradients of damage from sigma =
100 to 300 μm, steady-state glutamate levels in the probe range from ~3 to 10 μM (Fig.
4B1). Decreasing the glutamate diffusion coefficient from its value in buffer, which is
higher than in brain (Kullmann et al., 1999), increases the predicted steady state [Glu]
measured in the probe (Fig. 4B2). Increasing or decreasing the leak rate 𝐾 (Fig. 4B3)
also influences steady state [Glu] predicted in the probe volume.
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Fig. 4. Diffusion model of transporter contribution in dialysis measurement. (A 1) Cartoon
of metabolic damage in Gaussian region surrounding the microdialysis tube. (A 2)
Reduced uptake rate described by the Gaussian function in the damaged region. (B) PDE
numerical modeling describing the spatial profile of steady-state [Glu] with varying sigma
(B1), diffusion constant (B2) and leak rate (B3).
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4. DISCUSSION
Glutamate transporters limit receptor activity on different timescales in the brain by
restricting the spread of synaptically released glutamate as well as by maintaining low
ambient glutamate concentrations (for reviews, see Danbolt, 2001; Tzingounis and
Wadiche, 2007; Vandenberg and Ryan, 2013). The steady-state ambient concentration
of extracellular glutamate at any point in the brain reflects the balance of fluxes through
sources and sinks in the neuropil. The data presented here indicate that transporters can
establish steep concentration gradients when glutamate is supplied by passive diffusion
from a pseudo-infinite source. Although we have used the neuronal transporter EAAT3 in
these studies, its equilibrium thermodynamics are indistinguishable from the predominant
astroglial transporter EAAT2 (Levy et al.,1998). With EAAT3 transporter densities similar
to those reported for EAAT2 in hippocampal astroglial membranes (~10 4/μm2; Lehre and
Danbolt, 1998) the concentration gradient between a 10 μM source concentration and the
cell surface was found to exceed two orders of magnitude. The steepness of the gradient
formed would be further increased if diffusion were reduced, as for example in tortuous
neuropil (Kullmann et al., 1999). Conversely, reduction of transporter density or activity
will reduce the steepness of the gradient and increase [Glu] at the cell surface. Reduced
glutamate transport by loss or metabolic impairment is implicated in a broad range of
neuro degenerative disorders (Sheldon and Robinson, 2007) including stroke (Rossi et
al., 2000), traumatic brain injury (Goodrich et al., 2013), epilepsy (Coulter and Eid,2012),
Huntington’s disease (Faideau et al., 2010), ALS (Rothstein,2009), and Alzheimer’s
disease (Scimemi et al., 2013).
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While a precise knowledge of the concentration of ambient glutamate in various
brain regions in normal and neuropathological conditions is desirable, reports of this value
in the literature vary widely, with microdialysis approaches consistently providing
estimates approximately two orders of magnitude greater than estimates based on
electrophysiological measurement of tonic glutamate receptor activity. In the absence of
transporter inhibition, ambient [Glu] has been reported as being too low to activate AMPA
receptors, even when desensitization is pharmacologically blocked (Le Meur et al., 2007).
In contrast, ambient [Glu] has been reported to tonically activate high-affinity NMDA
receptors (Sahet al., 1989; Cavelier and Attwell, 2005; Le Meur et al., 2007;Herman and
Jahr, 2007). Several patch clamp studies in acute hippocampal slice have provided
estimates of ambient [Glu] based on analyses of the tonic NMDA receptor currents in CA1
pyramidal neurons. These have been reported as ~25 nM at 32° (Hermanand Jahr, 2007),
27–33 nM at 25°and 77–89 nM at 35° (Cavelierand Attwell, 2005), and 83–87 nM at 25°
(Le Meur et al., 2007).These estimates are not likely to be artifactually low due to loss of
glutamate from the surface of the slice, because inclusion of 2 μM glutamate in the
recording chamber did not alter the level of tonic receptor activity (Herman and Jahr,
2007). The major source of glutamate in these studies was of non-vesicular origin. A
range of possible molecular mechanisms may underlie glutamate release, including
glutamate-permeable anion channels, the cystine-glutamate exchanger xCT, and passive
membrane diffusion (Kimelberg et al., 1990; Baker et al., 2002; Cavelier and Attwell,2005;
for review see Cavelier et al., 2005). Elevation of ambient [Glu] by inhibition of glutamine
synthetase suggests that a major contribution of glutamate release is from glia (Cavelier
and Attwell, 2005; Le Meur et al., 2007).
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The data and the diffusion model presented here suggests that a thin layer of
damaged tissue with disrupted glutamate transport could underlie the significant
quantitative discrepancy between the ambient glutamate estimates provided by
electrophysiological studies in slices and those from microdialysis studies, which
generally report ambient [Glu] values in the range ≥2 μM (reviewed by Cavelier et al.,
2005; Featherstone and Shippy, 2008). Histological analyses of tissue surrounding
microdialysis probes provide evidence for a layer of damaged tissue up to hundreds of
microns surrounding the probe (Clapp-Lilly et al., 1999; Bungay et al.,2003; Amina et al.,
2003; Jaquins-Gerstl and Michael, 2009). Diffusion modeling suggests that disrupted
transport in this region could lead to artifactually large concentrations in the probe volume.
A critical assumption in our model is that the glutamate leak source is constant in a volume
of metabolically damaged tissue where transport is impaired. The precise spatial changes
in metabolic activity in a traumatized or ischemic region of tissue are unknown, but the
assumption that the leak is constant is conservative. For example, glutamate release is
increased by reversed glutamate transport due to impaired Na/K gradients during
metabolic challenge (Rossi et al., 2000). With a spatial distribution of transporter
impairment modeled with a Gaussian distribution, sigma values as small as 100 μm lead
to significant elevation of predicted probe [Glu] (Fig. 4B 1).
In addition to pharmacological block of glutamate uptake leading to increased
activation of AMPA and NMDA receptors (Jabaudon et al., 1999, 2000; Cavelier and
Attwell, 2005; Le Meuret al., 2007; Herman and Jahr, 2007), ischemia-induced reversed
transport also leads to large increases in extracellular [Glu] and pathological receptor
signaling (Rossi et al., 2000). Changes are also predicted by the probe diffusion model
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probe as a consequence of increases in basal glutamate release (Fig. 4B3). While the
value of extracellular [Glu] in the probe dialysate is predicted to significantly exceed
ambient [Glu] in healthy tissue far from the probe, the dialysate concentration is also
predicted to change in approximate proportion to changes in glutamate homeostasis in
distant tissue (Fig. 4B3). This behavior of the model is consistent with reported changes
in dialysate [Glu] in response to factors including transport block, ischemia, and trauma
(Benveniste et al., 1984; Hagberg et al., 1985; Baker et al., 2002; Del Arco et al., 2003;
Nyitrai et al., 2006).
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PREFACE
This chapter has been published and the text of the paper has not been changed.
Cheng B, Shchepakin D, Kavanaugh MP, Trauner D (2017). Photoswitchable Inhibitor of
a Glutamate Transporter. ACS Chem Neurosci 8(8): 1668–1672.
The synthesis of ATT and spectroscopy experiments were done by Bichu Cheng
in the Trauner lab. The electrophysiology experiments in Xenopus laevis oocytes were
done by Denis Shchepakin in the Kavanaugh lab.
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ABSTRACT
Excitatory amino acid transporters clear glutamate from the synaptic cleft and play
a critical role in glutamatergic neurotransmission. Their differential roles in astrocytes,
microglia, and neurons are poorly understood due in part to a lack of pharmacological
tools that can be targeted to specific cells and tissues. We now describe a
photoswitchable inhibitor, termed ATT, that interacts with the major mammalian forebrain
transporters EAAT1-3 in a manner that can be reversibly switched between trans (highaffinity) and cis (low-affinity) configurations using light of different colors. In the dark, ATT
competitively inhibited the predominant glial transporter EAAT2 with ~200-fold selectivity
over the neuronal transporter EAAT3. Brief exposure to 350 nm light reduced the steadystate blocker affinity by more than an order of magnitude. Illumination of EAAT2
complexed with ATT induced a corresponding increase in the blocker off-rate monitored
in the presence of glutamate. ATT can be used to reversibly manipulate glutamate
transporter activity with light and may be useful to gain insights into the dynamic
physiological roles of glutamate transporters in the brain, as well as to study the molecular
interactions of transporters with ligands.
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1. INTRODUCTION
Excitatory amino acid transporters (EAATs) play an essential role in the
mammalian central nervous system. They terminate the postsynaptic action of glutamate
by rapidly removing released neurotransmitter from the synaptic cleft and limit its
excitotoxic effect. To date, five different subtypes have been identified in mammals,
namely EAAT1-5 [1, 2, 3]. In human forebrain, the major neuronal transporter is EAAT3
and the major glial transporter is EAAT2 [4].
Due to their importance in synaptic transmission and glutamate homeostasis, the
EAATs have been subject to intense pharmacological studies, which has given rise to
several more or less selective inhibitors [5, 6, 7, 8, 9]. Threo-β-hydroxyaspartate (THA,
(1) in Figure 1) was discovered in the 1970s as a strong competitive inhibitor of Lglutamate uptake in rat brain slices [10] and was later identified as a blocker of the rodent
transporter EAAC1 [11]. Subsequently, Shimamoto and co-workers developed a series
of L-THA derivatives that are potent inhibitors of EAAT1−3. First, they identified L-threoβ-benzyloxyaspartic acid (L-TBOA, (2) in Figure 1) as a nontransportable blocker with
IC50 values in the low micromolar range [12]. L-TBOA serves as an important tool for the
investigation of the physiological role of these transporters [13]. It was recently
cocrystallized with an aspartate transporter homologue GltPh from Pyrococcus horikoshii
(pdb 2NWW), providing insight into the binding pose of these inhibitors [14] Introducing
substituents at the phenyl ring of TBOA increased its activity, as exemplified by the most
potent compound know to date, TFB-TBOA (3), which possesses an IC50 value in the low
nanomolar range [15].
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Figure 1. Chemical structure of EAAT inhibitors L-THA (1), L-TBOA (2), and TFB-TBOA
(3).
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In recent years, our group has succeeded in developing a range of synthetic
azobenzene photoswitches that can confer light sensitivity to biological systems [16, 17].
They can function either as freely diffusible photochromic ligands (PCLs) or as
photoswitchable tethered ligands (PTLs), and most recently as photoswitchable
orthogonal remotely tethered ligands (PORTL). These photopharmacology techniques
have placed ion channels, G-protein coupled receptors (GPCRs), enzymes, and even
lipids under the precise spatiotemporal control of light. They have found useful application
in the precise control of synaptic activity and neuronal excitability. Very recently, the
Wanner group has introduced an azobenzene photoswitch that targets the γ-aminobutyric
acid transporter 1 (GAT1) [18]. We now describe the development of a photoswitchable
azobenzene derivative of TFB-TBOA, termed Azo-TFB-TBOA (ATT, 4), that allows for
the precise and reversible control of EAAT activity with light. As such, it provides a new
way for modulating the synaptic concentrations of an excitatory neurotransmitter.
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2. RESULTS AND DISCUSSION
ATT was designed via “azologization” of TFB-TBOA [16]. This requires the
replacement of the diaryl amide functional group by a photoisomerizable diazene (N═N)
moiety. To gain rapid and reliable access to ATT, we developed a short and convergent
asymmetric synthesis that could also be adapted to other TBOA analogues. Previous
syntheses of TBOA and TFB-TBOA are either lengthy [19, 20], require an enzyme
catalyst that is not readily available and works only with limited substrate scope [21], or
produce the product in low enantiomeric purity [22]. Our synthesis began from readily
available D-diethyl tartrate (5). Its treatment with HBr in acetic acid (HOAc) afforded the
corresponding bromoacetate. Acetate hydrolysis in acidic ethanol and bromide
displacement with sodium azide in N,N-dimethylformamide (DMF) gave the alcohol (6) in
in 83% yield with 5:1 dr over three steps [23, 24]. The azobenzene fragment (9) was
prepared in good yield via a Mills reaction of aniline (7) and nitrosobenzene (8) and a
sequential Appel reaction. The coupling between fragments (6) and (9) was then
investigated. Under basic conditions, attempted O-alkylation afforded a complicated
mixture of products. However, with freshly prepared silver oxide (Ag 2O), the desired
product (10) was obtained in quantitative yield. The azide group was then reduced to the
amine under Staudinger conditions. The two diastereomers were separable by flash
chromatography (silica gel) at this stage. Finally, after hydrolysis of the ester in alkaline
solution and evaporation of the organic solvent, the product ATT (4) precipitated as a
hydrochloride salt from the aqueous solution upon acidification (Figure 2).
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Figure 2. Convergent and Asymmetric Synthesis of ATT (4).
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In its dark-adapted state, ATT (4) existed in its thermally stable trans-configuration.
ATT (4) behaved as a “regular” azobenzene and could be isomerized between its transand cis-configurations with blue (λ = 450 nm, τ = 1.93 min) and UV-A (λ = 350 nm, τ =
2.58 min) light, respectively. Photoisomerization could be repeated over many cycles
without obvious fatigue, as could be expected with an azobenzene switch. In its cis form,
ATT was also semistable in the dark and relaxed to the trans form slowly (τ = 146 min in
PBS solution) (Figure 3).
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Figure 3. Photoisomerization of ATT (4) in a PBS solution (5 μM). A) Light-induced
isomerization monitored by UV/Vis spectroscopy. B) Repeated cycles of trans-cis
isomerization of ATT with blue (λ = 450 nm) and UV-A (λ = 350 nm) light, and thermal
relaxation.
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With ample supplies of ATT (4) in hand, we proceeded to test its action on various
excitatory amino acid transporters. Because glutamate uptake is stoichiometrically
coupled to the flux of three sodium ions and one proton, with counter-flux of one
potassium ion, an electrical current results during glutamate uptake that can be measured
under voltage clamp conditions [25]. We examined the actions of ATT on glutamate
transport currents in Xenopus laevis oocytes previously injected with cRNA encoding
human transporters EAAT1–3 [26]. Perfusion of a subsaturating concentration lglutamate (30 μM) induced inward currents that were reversibly blocked by coapplication
of ATT in the absence of light (Figure 4A). The inhibition of l-glutamate transport currents
by ATT revealed subtype-selective effects of the blocker, with an order of affinity EAAT2
> EAAT1 > EAAT3. The ATT concentration-dependence for steady-state inhibition of 30
μM l-glutamate transport currents was determined by fitting data to inhibition isotherms
as described in the Methods (Figure 4B). The corresponding IC 50 values of ATT (nM) by
EAAT2, EAAT1, and EAAT3 were 0.9 ± 0.1, 8.1 ± 1.1, and 341.2 ± 19.5 nM, respectively.
Using the Cheng–Prusoff equation to obtain estimated K i values based on the IC50 values
and EAAT1–3 glutamate Km values [27], we obtained Ki estimates of 0.3 nM for EAAT2,
3.2 nM for EAAT1, and 165 nM for EAAT3. ATT did not induce a current in the absence
of l-glutamate in oocytes expressing any of the EAATs (see Figure 6).
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Figure 4. Voltage clamp recordings of currents in oocytes expressing glutamate
transporters EAAT1–3 reveal subtype-selective block by ATT in the absence of light. (A)
Representative oocyte expressing EAAT3 showing reversible block by dark-adapted
trans-ATT (1 μM) of current induced by 30 μM l-glutamate. Bars above trace indicate time
of perfusion of substrate and blocker. (B) Concentration-dependence of steady-state
inhibition of transport currents by trans-ATT yielded IC50 values (nM) for EAAT1 (circles),
EAAT2 (triangles), and EAAT3 (squares) of 8.1 ± 1.1, 0.9 ± 0.1, and 341.2 ± 19.5 nM,
respectively (mean ± SEM of n > 4 oocytes for each subtype; holding potential = -60 mV;
all recordings performed in dark conditions).
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To examine the effect of photoisomerization of ATT on its glutamate transporter
binding affinity, a bright monochromatic 350 nm light source was introduced by fiber optic
into the perfusion channel of the recording chamber just upstream of the cell, and the
steady-state ATT inhibition of currents induced by 30 μM l-glutamate was recorded in the
presence or absence of light. In the presence of 350 nm light, the concentrationdependence of inhibition of transport currents mediated by EAAT1–3 were right-shifted
between 3- and 14-fold, to 66.4 ± 4.9, 12.7 ± 1.4, and 1132 ± 51 nM respectively (n = 5;
Figure 5).
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Figure 5. Steady-state ATT concentration-dependence of block of transport currents
induced by 30 μM l-glutamate in the absence (open symbol) or presence (filled symbol)
of 350 nm light. The fitted IC50 values were shifted approximately 8-, 14-, and 3-fold for
EAAT1, EAAT2, and EAAT3, respectively. Holding potential = -60 mV.
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To test whether the photoisomerization of ATT could also occur while the molecule
was docked in the transporter binding site, we preincubated oocytes expressing EAAT2
with a near-saturating concentration of ATT (10 nM), and then tested the recovery of the
transport current following washout of the drug in the continuous presence of 30 μM lglutamate. In the absence of light, the transport current recovered slowly, reflecting the
slow unbinding kinetics of nanomolar affinity EAAT blockers [15, 27]. When pulses of 350
nm light were directed onto the surface of the oocyte during this washout phase, the
current recovery kinetics switched to a fast mode (Figure 6). When the light was switched
off, the remaining blocked fraction returned to a slow recovery mode, suggesting that the
remaining fraction of transporters remained blocked by the high-affinity isomer (Figure 6).
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Figure 6. Effects of 350 nm light on kinetics of recovery from ATT block indicate that the
blocker is capable of undergoing photoisomerization while in complex with the
transporter. In the dark, EAAT2-mediated currents induced by perfusion of l-glutamate
(30 μM) are blocked by preincubation with ATT (10 nM). Washout of blocker in the
presence of l-glutamate (30 μM) reveals a slow recovery from block that is accelerated
during 350 nm light pulse intervals indicated by blue bars. The timing of ligand perfusion
is indicated by bars above the trace. In the absence of ATT, light pulses had no effect on
holding currents nor glutamate-induced currents in oocytes expressing EAAT1–3 (not
shown). Holding potential = −20 mV.
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3. CONCLUSION
In conclusion, we have developed ATT as the first photochromic inhibitor of the
EAAT family of glutamate transporters. A short and asymmetric synthesis of ATT was
developed, which could potentially be used to procure TBOA itself and many of new
derivatives thereof. ATT can be reversibly switched between trans (high-affinity) and cis
(low-affinity) configurations using light of different colors. In its dark-adapted form, ATT
displayed subtype-selectivity with a subnanomolar affinity for the glial EAAT2 subtype,
the most abundant glutamate transporter in brain. Photoisomerization of the high-affinity
trans-configuration to the cis-configuration by 350 nm light reduced ATT affinity for EAAT2
by approximately 14-fold. Photoisomerization could also be induced in docked transporter
complexes within a discrete illuminated spatial domain, resulting in a corresponding
increase in the blocker off-rate monitored in the presence of glutamate. The results
demonstrate that ATT can be used to reversibly manipulate glutamate transporter activity
with light. As such, it may be a useful tool to gain insights into the physiological roles of
glutamate transporters in the brain, as well as to study the dynamic molecular interactions
of transporters with ligands. Studies in this direction are currently underway in our
laboratory.
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4. METHODS
Oocyte expression and recording: X. laevis oocytes (Ecocyte BioScience) were
injected with approximately 50 ng of human EAAT1, EAAT2, or EAAT3 cRNA [24], and
two-microelectrode voltage clamp recordings were performed 3–5 days later. Recording
electrodes (0.2–1.0 MΩ) were filled with 3 M KCl. Recording solution (frog Ringer)
contained (mM): 96 NaCl, 2 KCl, 1 MgCl2, 1.8 CaCl2, 5 HEPES pH 7.5. Recordings were
made with a GeneClamp 500 amplifier (Molecular Devices) and an analog–digital
converter (ADInstruments) interfaced to a Macintosh computer. Light was introduced into
the recording chamber perfusion channel or directly onto the oocyte with a fiber-optic light
guide coupled to a mononchrometer controlled by computer (Till). Data were analyzed
with LabChart and Kaleidagraph software. Responses to 30 μM l-glutamate were
recorded and steady-state inhibition curves to determine IC 50 values of ATT were
constructed by fitting current amplitude data to the expression: % inhibition = [ATT]/([ATT]
+ IC50). IC50 values are expressed as the mean ± SEM in at least 4 oocytes expressing
each transporter.
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PREFACE
The experiments in Xenopus laevis oocytes were done by Jill Farnsworth in the
Kavanaugh lab. The uptake experiments in mouse brain slices were done by Jill
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in brain slices were done by Denis Shchepakin in the Kavanaugh lab.
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ABSTRACT
D-serine is an endogenous coagonist of NMDA receptors, but the mechanism
of its regulation is poorly understood. Substantial evidence has been gathered
supporting the "serine-shuttle" theory about the flux of L-serine from astrocytes to
neurons (where L-serine is converted to D-serine by serine racemase) and the
complementary flow of D-serine from neurons to astrocytes (where D-serine is
degraded by D-amino acid oxidase). While the neuronal serine transporter is proposed
to be Na+-independent Asc-1/SLC7A10, the identity of astrocytic serine transporters
has not been established. Recent studies propose a Na +-dependent amino acid
exchanger, ASCT1/SLC1A4, for this role. We used a recently developed selective
blocker of ASCT1/SLC1A4, called BiPro, to study the transporter function in the
Xenopus oocyte expression system and acute hippocampal brain slices from mice.
We show that BiPro blocks Na+-dependent D-serine uptake. Application of BiPro to
acute mouse brain slice has a similar enhancing effect on NMDA receptors fEPSP as
the application of exogenous D-serine. Finally, BiPro does not have any direct effects
on exogenously expressed NMDA receptors or the NMDA receptor-mediated fEPSP
in ASCT1/SLC1A4 knockout mice.
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1. INTRODUCTION
N-methyl-D-aspartate receptors (NMDARs) play crucial roles in neural
development, synaptic transmission, and plasticity. NMDA receptor follows a complex
regulatory mechanism, which depends on binding two coagonists to its GluN1 (or
GluN3) and GluN2 subunits. The agonist of the GluN2 subunit is the amino acid
neurotransmitter glutamate, while there are two endogenous agonists for the
GluN1/GluN3 subunit: glycine and D-serine (Traynelis et al., 2010; Mothet et al.,
2015). It has been proposed that D-serine serves as a coagonist primarily for synaptic
NMDARs, while glycine acts primarily on extrasynaptic receptors (Papouin et al.,
2012). However, there are also some reports of glycine activity in synapses (Li et al.,
2013; Le Bail et al., 2015). Nevertheless, there is substantial evidence of the
importance of D-serine for synaptic NMDA receptor signaling (e.g., Mothet et al., 2000;
Hennenberger et al., 2010; Radzishevsky et al., 2013; Le Bail et al., 2015, Mothet et
al., 2015). The dysregulation of D-serine is associated with such disorders as
schizophrenia, epilepsy, and Alzheimer’s disease (Yamamori et al., 2014; Bardaweel
et al., 2014; Balu and Coyle, 2015; Kantrowitz et al., 2015; Madeira et al., 2015), as
well as age-related deficits in learning and memory (Junjaud et al., 2006; Mothet et al.
2006; Potier et al., 2010; Panizzutti et al., 2014). Moreover, mutations in the human
SLC1A4 gene have been associated with neurodevelopmental and cognitive deficits
in homozygous individuals (Damseh et al., 2015; Heimer et al., 2015; Srour et al.,
2015; Abdelrahman et al., 2019).
The enzyme serine racemase (SR) facilitates the isomeric synthesis of Dserine from L-serine (Wolosker et al., 2016) and appears to be the main source of D-
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serine in the brain. SR knockout mice were reported to have less than 15% of D-serine
level compared to that of control, to have a resistance to seizures, and to exhibit
impairments in NMDAR-mediated synaptic plasticity (Basu et al., 2009; Harai et al.,
2012; Miyoshi et al., 2012). SR appears to be localized to neurons (Wolosker et al.,
2016), and only about 10% of the astrocytes contain D-serine, while 90% of the
glutamatergic neurons contain D-serine (Ehmsen et al., 2013). The main source of Lserine in the brain that is required for D-serine synthesis is glucose, which is
metabolized by 3-phosphoglycerate dehydrogenase (PHGDH). Brain-specific deletion
of PHGDH gene significantly lowers both L- and D-serine levels (by over 80%),
suggesting a critical role of PHGDH in L-serine production and confirming the role of
L-serine as a D-serine precursor in the brain (Yang et al., 2010; Ehmsen et al., 2013).
Because PHGDH is an astrocytic enzyme, it would require a “serine-shuttle” that
transports the synthesized L-serine from astrocytes to neurons for further D-serine
conversion (Yamasaki et al., 2001; Yang et al., 2010; Ehmsen et al., 2013; Wolosker
and Radzishevsky, 2013). D-amino acid oxidase (DAAO) is the only known enzyme
that catabolizes D-serine, and it is present mainly in glial cells (Sacchi et al., 2012).
This suggests the existence of a D-serine sink via uptake by astrocytes for
degradation.
These prior findings suggest that D-serine regulation involves two Na +dependent (ASCT1-2 or SLC1A4-5) and one Na+-independent (SLC7A10) amino-acid
exchangers that couple D-serine uptake or release to countertransport of other neutral
amino-acids.

The

Na+-independent

neuron-specific

alanine-serine-cysteine

transporter-1 (Asc-1/SLC7A10) has a high affinity for D-serine and is assumed to be
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the major pathway for D-serine release (Fukasawa et al., 2000; Helboe et al., 2003;
Maucler et al., 2013; Rosenberg et al., 2013; Sason et al., 2017). The claim is based
on a wide variety of evidence. Rosenberg et al. (2013) showed that D-isoleucine, a
selective Asc-1 substrate, enhances LTP at the hippocampal CA1-CA3 by releasing
endogenous D-serine from neurons. Maucler et al. (2013) used a D-serine biosensor
in vivo to directly test the function of Asc-1 and demonstrated its importance in Dserine regulation. Sason et al., (2017) reported a substantial decrease in D-serine
efflux in Asc-1 knockout mice acute brain slices, and this effect was mimicked by
application of Asc-1 blocker in wild-type mice.
The efflux of intracellular D-serine from primary astrocyte cultures was
identified to be Na+- and amino-acid dependent, which led to the suggestion that the
Na+-dependent

counter-transporter

could

belong

to

the

alanine/serine/cysteine/threonine transporter (ASCT) subfamily of solute carrier family
1 comprising SLC1A4 and SLC1A5 (Ribeiro et al., 2002; Maucler et al., 2013). Ribeiro
et al. (2002) reported that D-serine exchange appeared to be coupled with L-serine.
However, due to previously reported data (Shafqat et al., 1993) claiming that
ASCT1/SLC1A4 does not recognize D-serine,

succeeding studies focused on

ASCT2/SLC1A5. This was paradoxical since ASCT2/SLC1A5 is mainly expressed
outside of the CNS (Utsunomiya-Tate et al., 1996), while ASCT1/SLC1A4 appears to
be widely expressed in the brain (Arriza et al., 1993). Recently, Foster et al. (2016)
demonstrated that ASCT1/SLC1A4 does transport D-serine with physiologically
relevant kinetic parameters. It was suggested that ASCT1/SLC1A4 regulates the
uptake of D-serine in the brain (Kaplan et al., 2018). Accumulating evidence now
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suggests that SLC1A4-mediated transport is a strong candidate for the missing link in
the astrocyte sink hypothesis of extracellular D-serine homeostasis (see Fig. 1 for the
hypothesized mechanism of influx-efflux of D-serine).
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Fig. 1. Hypothesized mechanism of a “serine-shuttle” between astrocytes (right) and
neurons (left). L-serine is synthesized from blood glucose (transported by Glut1) in
astrocytes with help of 3-phosphoglycerate dehydrogenase (PHGDH) enzyme. L-serine
efflux from astrocytes is performed primarily by neutral amino acid exchanger
ASCT1/SLC1A4, and L-serine uptake is done by neuronal neutral amino acid exchanger
Asc-1. In neurons, an enzyme serine racemase (SR) catalyzes the transformation of Lserine to D-serine. D-serine follows the complementary to L-serine flux from neurons to
astrocytes, where its degradation is mediated by the D-amino acid oxidase (DAAO)
enzyme. It is possible that L-serine flux from astrocytes to neurons could also be
facilitated by other neutral amino acid exchangers to a lesser extent.
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2. MATERIALS AND METHODS
Ethics statement
Mice and Xenopus laevis used in this study were treated in a manner to minimize
suffering. Mice were anesthetized with isofluorane and decapitated following NIH and the
University of Montana regulations; the study was approved by the University's IACUC
(AUP 045-18). Xenopus laevis were anesthetized with tricaine before oocyte removal in
accordance with NIH and University of Montana IACUC regulations (IACUC protocol
approval 065-11MKBMED-122111)

Mouse hippocampal slice preparation and recording
SLC1A4-KO mice on a C57BL/6 background were made using an exon-targeted
CRISPR/CAS9 protocol by Teresa Gunn at the McLaughlin Research Institute. Mice were
anesthetized with isofluorane and decapitated following the University of Montana IACUC
regulations (AUP 045-18). The brain was rapidly dissected and placed in an ice-cold
solution containing (in mM): 79.9 NaCl, 24 NaHCO3, 25 glucose, 70 sucrose, 2.5 KCl,
1.25 NaH2PO4. The solution was saturated with 95% O2 and 5% CO2 (pH 7.3). 300 µm
thick coronal hippocampal slices were cut using a vibratome (Compresstome® VF-2000Z Vibrating Microtome), then hemisected and placed in the artificial cerebral spinal fluid
(ACSF). ACSF recipe (in mM): 126 NaCl (or 126 Choline Cl in Choline/ASCF), 2.5 KCl,
1.2 MgCl2 (or 0 MgCl2 in Mg-free ASCF), 2.4 CaCl2, 1.2 NaH2PO4, 11.4 glucose, and
21.4 NaHCO3 saturated with 95%O2 and 5% CO2 (pH 7.3) and maintained at 37°C.
Slices were allowed at least 1 hour to recover before being placed in a submersion-type
recording chamber perfused at 2.0–3.0 ml/minute with ACSF at 24°C (room temperature)
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or 32°C. In experiments with Mg-free ACSF, the slices recovered in ACSF and perfused
with Mg-free ACSF. Field excitatory postsynaptic potentials (fEPSPs) were recorded in
CA1 region of the hippocampus using glass electrodes filled with ACSF. Recordings were
made with a computer-controlled Multiclamp 700B amplifier from Molecular Devices, and
data were acquired at 20 kHz and filtered at 5–10 kHz. Slices were visualized on an
upright fixed-stage microscope (Olympus BX51WI). The acquisition and analysis
software was LabChart (version 8.1.13). fEPSPs were induced by stimulation of Schaffer
collaterals with 100 µs current pulses between 0.1 mA–0.8 mA administered through
ACSF-filled stimulating pipettes.

Oocyte electrophysiology and radiolabeled uptake
Approximately 50 ng of human SLC1A4, or SLC7A10 and SLC3A2 was
microinjected into stage V–VI Xenopus oocytes. Recordings were made 3-5 days later.
Recording solution (frog Ringer) contained 96 mM NaCl, 2 mM KCl, 1 mM MgCl 2, 1.8 mM
CaCl2, and 5 mM HEPES pH 7.5. Oocytes were voltage-clamped with GeneClamp 500
amplifiers and Molecular Devices analog-digital converters interfaced to a PC or
Macintosh computers. Microelectrodes were pulled to resistances between 0.2 and 1 MΩ
filled with 3 M KCl. The recording chamber was grounded with a 3 M KCl-filled agar bridge
connecting to a 3 M KCl reservoir containing an Ag/AgCl electrode. Data were acquired
with Axograph software. For radiolabeled uptake assays, oocytes were incubated in
Ringer solution with 100 nM [3H]D-serine (American Radiolabeled Chemicals). After the
uptake, oocytes were washed 3 times with 4°C buffer, lysed in 1.0% sodium dodecyl
sulfate, and their radioactivity was measured by liquid scintillation spectroscopy.
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3. RESULTS
3-biphenyl-4-hydroxyproline is a high-affinity specific blocker of ASCT1/SLC1A4
To study the properties of ASCT1/SLC1A4, we implemented a recently developed
blocker 3-biphenyl-4-hydroxyproline (BiPro, see Fig. 2A) with a submicromolar affinity for
the transporter (Kavanaugh et al., 2016). The application of D-serine to voltage-clamped
oocytes expressing ASCT1/SLC1A4 resulted in outward current, while BiPro blocked the
leak conductance (see Fig 2B). The D-serine-activated current had the same reversal
potential as the leak current (Fig. 2C). ASCT1/SLC1A4 is a member of SLC1 and 40%
homologous with other members of this family, glutamate transporters, called excitatory
amino acid transporter 1-3 (EAAT1-3 or SLC1A3-1, respectively) (Kanai et al., 1993). The
transport facilitated by all members of SLC1 is Na+-dependent, but, unlike glutamate
transporters, ASCT1/SLC1A4 does not depend on intracellular K + concentration and
facilitates electrically neutral exchange, i.e., there is no stoichiometric charge
translocation. Similar to orthologous glutamate transporters, ASCT1/SLC1A4 exhibits
thermodynamically uncoupled chloride channel activity associated with a substrate
transport (Zerangue and Kavanaugh, 1996; Bröer et al., 2000). Therefore D-serineactivated current and leak current shown in Fig. 2 correspond to the flow of chloride ions,
which explains why their reversal potentials are close to the reversal potential of chloride
ion ECl~-24mV in accord with previous measurements (e.g., Barrish 1983; Zerangue and
Kavanaugh, 1996).
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Fig. 2. A. The structure of 3-biphenyl-4-hydroxyproline (BiPro). B. Currents recorded in
Xenopus oocytes expressing ASCT1/SLC1A4 neutral amino acid exchanger. Uptake of
applied extracellular D-serine (100 μM) is accompanied by uncoupled anion
conductance. The application of BiPro (300 nM) blocks the persistent leak conductance.
C. The IV relationship of D-serine- and BiPro-induced currents. Holding potential -30
mV.
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Next, we studied the specificity of BiPro at ASCT1/SLC1A4. The uptake of
radiolabeled [3H]D-serine was reduced by the application of 300nM BiPro to a level not
significantly different from the uninjected oocytes (Fig. 3A). At the same time, BiPro did
not have any significant effect on [3H]D-serine uptake in oocytes expressing asc1/SLC7A10 transporter (Fig. 3B). BiPro (1 µM) did not have any significant effect on the
10 μM glutamate-induced current in EAAT2 glutamate transporter, the primary glutamate
transporter in the brain (Haugeto et. al., 1996; Tanaka et. al., 1997; Danbolt 2001;
Matsugami et. al., 2006; Holmseth et. al., 2012) ([1 μM BiPro + 10 μM glutamate]-induced
current with 97 ± 7% amplitude of the 10 μM glutamate current, n=3; data not shown).
Co-application of 1 μM BiPro with [1 μM glutamate + 1 μM D-serine] also did not
significantly affect the responses in oocytes expressing N-methyl-D-aspartate receptors
(subunit composition: GluN1/GluN2A and GluN1/GluN2B; 101 ± 2% and 103 ± 1% of
control, respectively, n=12 each; data not shown).

175

176

Fig. 3. A. Uptake of 100 nM radiolabeled [3H] D-serine in Xenopus oocytes expressing
ASCT1/SLC1A4 was blocked to values not statistically significant from uninjected oocytes
(p-value > 0.2, n=6). B. BiPro did not block any statistically significant portion of 100 nM
radiolabeled [3H]D-serine in oocytes expressing Asc-1 (SLC7A10; in order for it to form a
functional dimer, it was coexpressed with SLC3A2).
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ASCT1/SLC1A4 facilitates extracellular D-serine uptake in the brain.
To investigate the role of ASCT1/SLC1A4 in the transport of endogenous D-serine,
we investigated the effect of BiPro in acute hippocampal slices of WT mice. We recorded
the uptake of radiolabeled [3H]D-serine in mouse slices. We dissected coronal slices in
half and compared uptake in the presence and absence of 1 μM BiPro for each pair of
hemisections (Fig. 4). There was a significant decrease in the [ 3H]D-serine when BiPro
was co-applied. We wanted to test whether the unblocked portion of the uptake
corresponds to ASCT1/SLC1A4 or not. We repeated the experiment but substituted
sodium for choline to eliminate ASCT1/SLC1A4 Na+-dependent uptake. BiPro did not
have a significant effect on the Na+-independent uptake (presumably by asc-1), and it
was similar to the unblocked portion of the uptake from the previous experiment.

178

179

Fig. 4. Na+-dependent uptake of 100 nM radiolabeled [3H] D-serine in acute mouse brain
slices (300 μm) was inhibited by 1 μM BiPro (p < 0.01). The substitution of sodium with
choline revealed similar decrease in D-serine uptake, which was robust to BiPro
application. The slices were hemisected with one half used as a control in regular ASCF,
the responses in the second half were normalized to the control hemisection. The slices
were kept at 32°C.
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D-serine and glutamate are coagonists of NMDA receptors. If ASCT1/SLC1A4 is
a major transport sink of extracellular D-serine in the brain, then by blocking it, the ambient
D-serine concentration will rise. We recorded fEPSPs in Mg-free aCSF with NBQX to
relieve the magnesium block of NMDA receptors and block AMPA/kainate receptors
response. After recording the baseline, we co-applied BiPro and looked for changes in
fEPSP dynamics. However, the results appeared inconsistent: we saw facilitation in about
60% of cases at room temperature and 50% cases at physiological temperature (Fig. 5).
Therefore, it is possible that either D-serine was already present at saturating
concentrations in non-responsive slices or there are other mechanisms of D-serine
uptake besides ASCT1/SLC1A4.
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24°C

32°C
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Fig. 5. NMDA fEPSP after the application of BiPro in acute hippocampal brain slices of
WT mice. Each column depicts a series of experiments done at 24°C (left column) and
32°C (right column). Some responses showed clear facilitation (top traces; “response”
group on bar charts), while others did not (bottom traces; “no response” group on bar
charts). AMPAR responses (dark gray) were recorded in aCSF before switching to Mgfree aCSF + NBQX solution, which blocked the response (light gray). After Mg 2+ was
washed out, the NMDAR responses (green) were recorded. The following co-application
of BiPro facilitated NMDAR responses (NMDAR-BP, red) in some experiments. In
experiments where the effect of BiPro took place, it was washed out, which returned
NMDAR responses to their base level (NMDAR-Wo, light blue; absent in the bottom “no
response” traces). NMDAR responses were blocked by the application of AP5 (another
light gray). All responses were recorded for at least 10 minutes after they stabilized. The
bar charts show all NMDAR-BP responses, which were normalized to corresponding
NMDAR responses (before the application of BiPro), i.e., the value of 1 corresponds to
no change. At both temperatures, response amplitudes were statistically different from no
response amplitudes and the base value of 1 (all p-values < 0.01), while no response
amplitude was not statistically different from 1 (p-values > 0.05). The BiPro concentration
varied between the experiments (300 nM – 20 μM) with no correlation between
concentration and fEPSP facilitation (p-value > 0.05, significance of the correlation
coefficient test). The numbers of mice and slices are indicated under the corresponding
bars. The statistics are given as mean ± std. A. Recorded at 24°C; response amplitude:
1.26 ± 0.06; no response amplitude: 0.99 ± 0.04. B. Recorded at 32°C; response
amplitude: 1.29 ± 0.15; no response amplitude: 0.99 ± 0.05.
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A similar inconsistency in fEPSP facilitation by application of exogenous D-serine
is mentioned in several studies (e.g., Junjaud et al., 2006; Rosenberg et al., 2013). One
of the possible explanations for this is the variable D-serine concentration due to some
uncontrolled experimental factors. There is some evidence that the ambient D-serine
oscillates throughout the wake-sleep cycle (Papouin et al., 2017). Namely, it appears that
D-serine concentration drops during sleep and rises during the awake state. Moreover, a
novel or enriched environment seems to facilitate the D-serine elevation mechanism while
the subjects are awake. In our experiments, the mice were kept in a facility with controlled
light and dark cycles. The mice were brought from the facility to the lab approximately 3.5
hours after the beginning of the light cycle (i.e., presumably 3.5 hours of sleep). Then,
they were left in an unfamiliar to them lab environment for a varying amount of time before
the surgery. We found a strong dependence between the effect of BiPro on NMDARmediated fEPSP and a delay before the surgery. This pattern was consistent across all
experiments with various temperatures and BiPro concentrations (Fig 6A). We also found
that the amount of facilitation appears to be time-dependent as well (Fig 6B).
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Fig. 6. Time dependence of NMDAR fEPSP amplitude sensitivity to BiPro. A. NMDAR
fEPSP amplitudes after the application of BiPro were compared to their pre-application
values and classified as either “response” group (facilitation by more than 10%) and “no
response” group (less than 10%). Measurements were done across all experiments with
varying concentrations of BiPro (300 nM – 20 μM) and two different temperatures (24°C
and 32°C). There was no correlation between BiPro concentration and fEPSP facilitation
(p-value > 0.05, significance of the correlation coefficient test). The red line is a fitted
logistic regression with the trend being significant (Wald test p-value < 0.01; n=45, 21 WT
mice). B. fEPSP facilitation after the application of 3μM of BiPro at 24°C as a function of
time. Facilitations before and after the surgery delay threshold of 2.5 hours were
significantly different (p-value < 0.01; n=20, 9 WT mice). Red line is a logistic regression
function drawn to indicate the trend.
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We next compared the ASCT1-KO with WT mice by repeating. the experiments
with a minimal delay after waking before the surgery to keep endogenous D-serine
concentration low. Following the application of BiPro, drug was washed out to allow the
fEPSP to return to its base level, and a saturating concentration of D-serine (100 μM) was
applied. We compared the facilitation of NMDAR-mediated fEPSPs by BiPro and D-serine
between WT and ASCT1-KO mice genotypes. There was a significant and comparable
fEPSP facilitation in WT mice by both BiPro and D-serine, but not in KO mice (Fig. 7). To
further compare the effects of BiPro- and exogenous D-serine-induced fEPSP facilitation
we plotted their effects against each other across various concentrations and
temperatures in all experiments where both drugs were used in a single slice. We found
a strong correlation between the variables (Fig. 8).
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Fig. 7. Facilitation of NMDAR fEPSP by BiPro (3 μM) and D-serine (100 μM) in WT and
ASCT1-KO mice. A. The numbers of mice and slices are indicated next to the
corresponding genotypes. Facilitations by BiPro and D-serine were not significant
different within each phenotype, but were significant different between the phenotypes (pvalues > 0.05 within phenotype, and p-values < 0.01 between phenotypes, one-way
ANOVA with post-hoc Tukey HSD test). B. Representative trace. The experiment is
identical to the one in Fig. 5, but after the washout 100 μM of D-serine was applied
(NMDAR – green, NMDAR-BP [co-application of BiPro] – red, NMDAR-Wo [washout] –
light blue, NMDAR-DS [co-application of D-serine] – orange, NMDAR blocked by AP5 –
grey).

189

190

Fig. 8. Correlation between BiPro- and D-serine-induced facilitation of NMDAR fEPSP
across different experimental conditions. Recordings are grouped according to their
temperature (24°C or 32°C), mouse genotype (WT or KO), BiPro concentration (3 μM, 10
μM, or 20 μM), and response (“response” or “no response” group). Correlation coefficient
is 0.919 (p-value < 0.01, significance of the correlation coefficient test; n=31, 6 WT mice,
4 KO mice, ).
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4. DISCUSSION
D-serine is an endogenous NMDA receptor coagonist (Mothet et al., 2000;
Hennenberger et al., 2010; Radzishevsky et al., 2013; Le Bail et al., 2015, Mothet et al.,
2015). Neuron-specific enzyme SR facilitates the conversion of L-serine to D-serine
(Wolosker et al., 2016), while L-serine is produced in astrocytes from glucose (Yang et
al., 2010; Ehmsen et al., 2013). The catabolism of D-serine also happens in astrocytes
by oxidative deamination (Sacchi et al., 2012). The apparent flow of L-serine from
astrocytes to neurons and complementary flow of D-serine in the opposite direction was
named a “serine-shuttle” (Yamasaki et al., 2001; Yang et al., 2010; Ehmsen et al., 2013;
Wolosker and Radzishevsky, 2013). While the L- and D-serine exchanger in neurons was
identified as Asc-1, the identity of the astrocytic D-serine transporter has been elusive
(Fukasawa et al., 2000; Helboe et al., 2003; Maucler et al., 2013; Rosenberg et al., 2013;
Sason et al., 2017). Recent studies proposed ASCT1/SLC1A4 as a potential candidate
for this role (Foster et al., 2016; Kaplan et al., 2018). A model of the "serine-shuttle"
including ASCT1/SLC1A4 is depicted in Fig. 1.
We demonstrated the efficacy and specificity of a recently developed 3-aryl-4prolinol non-transportable blocker of ASCT1/SLC1A4, called BiPro (Kavanaugh et al.,
2016).

BiPro

blocked

the

D-serine

uptake

in

Xenopus

oocytes

expressing

ASCT1/SLC1A4 (Fig. 3) but had no effect on NMDA receptors, glutamate transporters,
or Asc-1/SLC7A10. Uptake assays in acute brain slice demonstrated that BiPro blocks
Na+-dependent D-serine uptake, but does not affect Na+-independent D-serine
exchange, likely facilitated by Asc-1 (Fig. 4). The experiment indirectly supports the
mechanism proposed in Fig. 1, as ASCT1/SLC1A4 transport is primarily sodium-
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dependent (Ribeiro et al., 2002; Yamamoto et al., 2004; Maucler et al., 2013), while Asc1 functioning is sodium-independent (Fukasawa et al., 2000; Nakauchi et al., 2000;
Helboe et al., 2003; Matsuo et al., 2004; Rutter et al., 2007).
New studies start to report the oscillation of D-serine ambient levels thought the
day and its involvement in a sleep-wake cycle in different species (e.g., Papouin et al.,
2017). D-serine appears to be present at non-saturating concentrations at least in some
regions of the brain, e.g., hippocampus (Wilcox et al., 1996; Bergeron et al., 1998). We
used acute hippocampal slices of mice to study the effects of BiPro on NMDAR-induced
fEPSP. We found a strong congruence between the application of BiPro and exogenous
D-serine further supporting the proposed role of ASCT1/SLC1A4 in establishing D-serine
homeostasis (Fig. 8). Interestingly, we also found a strong association between the
responses to BiPro or exogenous D-serine and a sleep-wake cycle (Fig. 6). In agreement
with the proposed mechanism, the recordings from ASCT1-KO mice did not exhibit any
effects of BiPro application. Exogeneous D-serine also did not affect NMDAR-induced
fEPSPs in ASCT1-KO mice brain slices, suggesting that it present at saturating
concentration throughout the day.
In conclusion, our findings are in good agreement with recent studies that focus on
the ASCT1/SLC1A4 transporter and its role in D-serine regulation (Foster et al., 2016;
Kaplan et al., 2018). We tested the efficacy and specificity of a novel ASCT1/SLC1A4
blocker BiPro (Kavanaugh et al., 2016) and demonstrated its ability to permute D-serine
homeostasis. Kaplan et al. (2018) reported that ASCT1/SLC1A4 knockout mice exhibit
decreased hippocampal volume, motor, and learning deficits. Recent exome analysis also
revealed that recessive mutations of ASCT1/SLC1A4 transporter (E256K, R457W, and
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Y191*) are associated with developmental delay, microcephaly, hypomyelination, seizure
disorder, spasticity, and thin corpus callosum (Damseh et al., 2015; Heimer et al., 2015;
Srour et al., 2015; Abdelrahman et al., 2019). E256K mutation is particular has a carrier
frequency of 0.7% in the Ashkenazi-Jewish (Damseh et al., 2015), and it appears to result
in a gain of function in ASCT1/SLC1A4. Further research on the mechanism of the Dserine regulation is required to study these disorders. BiPro showed to be a useful
research tool, and further studies are indicated to evaluate its potential usefulness in
therapeutic applications.
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CONCLUSION
Glutamate is the predominant excitatory neurotransmitter in mammalian CNS
(Harris, 1994). As with all neurotransmitters, its neurological activity is defined by the
intramembranous proteins it interacts with. Following exocytosis, L-glutamate diffuses
freely within a complicated network of extracellular space in the brain where it can interact
with various target receptors. Released transmitter molecules will eventually be removed
from the space surrounding cells by excitatory amino acid transporters (EAATs), proteins
localized in the plasma membrane of neuronal and glial cells. It is an interplay among the
processes of release, diffusion and uptake by EAATs, that determines the temporal and
spatial dynamics of L-glutamate concentration (Otis and Kavanaugh, 1999). The work
presented in this dissertation focuses on the investigation of glutamate receptors and
transporters.
We started the discussion with a common issue in biological models:
overparameterization. The issue of overparameterization is a naturally occurring problem.
The modelling of any process requires to include all known internal mechanisms of the
system. The resulting models have a general character in a sense that they should be
able to describe the behavior of the system in any condition and give a definitive answer
on the behavior of the modeled process. However, it is often impossible to estimate all of
the parameters of the model in a single experiment or even in a series of experiments,
i.e., some parameters have little to no influence on the behavior of the system under a
particular set of experimental conditions. Thus, the problem of the model
overparameterization is not an intrinsic fallacy of the model but rather the mismatch
between the model and the available data used to estimate the parameters of the model.
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In such cases, the model should be simplified and reduced to a smaller one with fewer
variables and/or parameters. In the first chapter we applied this reasoning to glutamate
transporters EAAT1-3. They play a crucial role in removing ambient glutamate from the
extracellular space. We discussed the existing mathematical models of EAATs and the
fact of their overparameterization with respect to the available data. One of the apparent
outcomes of the use of overparameterized models is the discrepancy in values of reported
parameters. As a consequence, even such basic properties as the average turnover rate
of transporters varies over 1-2 orders of magnitude in the literature. We proposed a
solution to this problem by simplifying the complicated models to smaller and simpler ones
using mathematical reduction techniques. However, such reductions must be tailored to
the experimental conditions, and one should always start with a generalized "full" model
and work the way through the procedure. We demonstrated the technique by obtaining
statistically reliable turnover rates of EAATs from a series of experiments. Interestingly,
our estimates were consistent with the some reported in the literature for EAAT1-2 but
none for EAAT3. It is worth mentioning that the concentration of EAAT3 is relatively low
in the brain to the extent that it was hard to identify them in the first place (Danbolt, 2001).
That poses an obstacle in establishing the degree to which EAAT3 plays a role in
glutamate uptake.
Next, we constructed a 3D diffusion model of a single synapse to simulate the
release and the uptake of glutamate, using EAATs turnover rates we found. The
pharmacological block of EAATs prolongs glutamate transmission in synapses (e.g., Otis
et al., 1996; Asztely et al., 1997; Lozovaya et al., 1999; Arnth-Jensen et al., 2002; Sun et
al., 2011). However, even the highest estimates of the EAATs turnover rates are several
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folds slower than the time course of the glutamate in the synaptic cleft during
transmission. Consistently with the latter fact, our stimulations demonstrated that EAATs
have an insignificant effect on the dynamics of the glutamate concentration during
synaptic transmission on a scale of a single synapse. According to the model, the
clearance of a synaptic cleft is achieved by passive diffusion of the glutamate outside of
the synapse. Let us note that the simulated dynamics of glutamate in the synapse were
faster compared to the previous reported values (Clement et a., 1992). It is likely because
the constructed model predicts the behavior on a scale of a single synapse, while
multisynaptic properties were not taken in the account, i.e., spillover (Venture and Harris,
1999). Moreover, some of the more complicated transporter properties were not modeled,
e.g., an aqueous cavity caused by trimeric structure of the transporters that can act as a
diffusion barrier and trap glutamate molecules (Leary et al., 2011). Together, that can
explain the discrepancy between our findings and the mentioned reports of the EAATs
blockage effect on the time-course of synaptic transmission, as they make use of
multisynaptic systems. The blockage of EAATs in a multisynaptic systems will include
extrasynaptic transporters as well and rise an ambient glutamate levels within seconds.
The elevated ambient glutamate concentration will slow down the passive diffusion of the
glutamate from the synapses and might be the cause of the prolonged transmission. To
test this hypothesis, one needs to construct a more complicated multisynaptic model that
includes modeling of a complex geometric structure of many synapses. If the hypothesis
is proved to be valid, then it suggests EAATs to be the main drives of control of both
ambient and phasic glutamate concentrations.
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In the second chapter, we reported the ability of transporter to establish an
effective diffusion gradient in the vicinity of the cell surface. The gradient would help
prevent neuronal excitotoxicity of the postsynaptic and the prolonged activation of
receptors from ambient glutamate. The ambient glutamate concentration plays a role in
both of these situations. There is an existing inconsistency in estimating ambient
glutamate concentration in the brain between electrophysiology and microdialysis
methods. We proposed that a microdialysis catheter damages the tissue in a small vicinity
of the penetration point, which causes excessive leak of glutamate and disruption of Na +and K+-dependent transport. As a consequence, glutamate concentrations are
significantly elevated over normal physiological levels. We modeled the process as proof
of concept. The simulation revealed that if the true ambient glutamate concentration is
the one given by the electrophysiology method, the microdialysis method will yield the
results consistent with the ones reported in the literature. Due to glutamate gradient
phenomenon the term “ambient” glutamate concentration becomes harder ot define as it
is not describable by a single value. In that context, electrophysiological measurement
based on the tonic activation of NMDA receptors, that are also affected by the glutamate
gradient phenomenon, are likely to yield underestimation of “ambient” glutamate
concentration far from the cell surface, while being adequate in the proximity of the cell
membrane.
In the third chapter, we focused on new potential pharmacological tools for EAAT
research. We developed and studied the first photoswitchable EAAT blocker, called ATT.
We demonstrated that ATT switches between its cis- and trans- conformations upon
stimulation with a light of certain wavelengths. Different conformations of ATT has
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different EAAT affinity. Interestingly, we demonstrated that ATT can readily change its
shape even while the molecule is docked to the EAAT binding site in response to
photoirradiation. The properties of ATT allow to switch between its low- and high-affinity
states, allowing to effectively switch between “two” different blockers almost
instantaneously. ATT is a potentially useful tool for further research and clinical studies.
In the final fourth chapter, we switch our focus from glutamate transporters to the
NMDA glutamate receptor. NMDARs are unique in their requirement to bind not only
glutamate but also coagonist D-serine to become activated. However, the mechanism of
D-serine regulation in the brain is poorly understood and incomplete. We propose
ASCT1/SLC1A4, a neutral amino acid transporter, as the main sink of the ambient Dserine and the final piece of the puzzle. We developed an ASCT1/SLC1A4-specific
blocker and reported a series of experiments in Xenopus oocytes and brain slices as the
evidence to support our theory. The theory demonstrates the importance of future
research of the topic provides. For example, it provides a possible explanation why
mutations

in

the

human

ASCT1/SLC1A4

gene

have

been

associated

with

neurodevelopmental and cognitive deficits in homozygous individuals (Damseh et al.,
2015; Heimer et al., 2015; Srour et al., 2015; Abdelrahman et al., 2019). Our findings
suggest ASCT1/SLC1A4 to be a potential pharmacological target in diseases caused by
misregulation of NMDAR coagonist D-serine, and BiPro as one of the tools in the future
studies.
In conclusion, the findings reported in this work deepens our knowledge about the
neurotransmitter glutamate and expand our understanding of the nature of EAATs and
NMDAR. The dissertation described novel pharmacological tools, the photoswitchable
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compounds, that can be useful in future research. We also describe a useful modeling
approach and demonstrate its effectiveness in the example of EAAT modeling. We
recently published another application of this technique to NMDAR modeling (Shchepakin
et al., 2020). However, the methodology is quite general and can be applied to a wide
range of problems.
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